|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
chloroxylenol inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein] |
CTD |
PMID:33049310 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
chloroxylenol binds to and results in increased activity of ESR1 protein |
CTD |
PMID:33049310 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
chloroxylenol binds to and results in increased activity of ESR2 protein |
CTD |
PMID:33049310 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
chloroxylenol binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:33049310 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
chloroxylenol binds to and results in increased activity of PPARG protein |
CTD |
PMID:33049310 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Scn4a |
sodium voltage-gated channel alpha subunit 4 |
affects activity multiple interactions |
ISO |
chloroxylenol affects the activity of SCN4A protein polymorphism chloroxylenol binds to and results in decreased activity of SCN4A protein |
CTD |
PMID:11282107 PMID:14662728 |
|
NCBI chr10:91,246,936...91,296,670
Ensembl chr10:91,246,936...91,296,545
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions |
ISO |
chloroxylenol binds to and results in increased activity of THRB protein |
CTD |
PMID:33049310 |
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO |
aminocarb results in decreased activity of ACHE protein |
CTD |
PMID:2086312 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
affects binding multiple interactions |
ISO |
[Chromones analog binds to cuprous chloride] which binds to AKT1 protein [Chromones analog binds to cuprous chloride] which results in decreased activity of AKT1 protein |
CTD |
PMID:16789737 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases activity increases expression |
ISO |
cuprous chloride results in increased activity of NQO1 protein cuprous chloride results in increased expression of NQO1 mRNA |
CTD |
PMID:9029048 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
S100a13 |
S100 calcium binding protein A13 |
multiple interactions |
ISO |
[Calcium Chloride co-treated with cuprous chloride] binds to and affects the folding of S100A13 protein; cuprous chloride binds to and affects the folding of S100A13 protein |
CTD |
PMID:16766622 |
|
NCBI chr 2:175,999,439...176,005,933
|
|
G |
Tf |
transferrin |
multiple interactions |
ISO |
cuprous chloride inhibits the reaction [TF protein results in increased uptake of Iron] |
CTD |
PMID:11335103 |
|
NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511
|
|
|
G |
Aass |
aminoadipate-semialdehyde synthase |
increases expression |
ISO |
cypermethrin results in increased expression of AASS mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 4:51,606,461...51,663,136
Ensembl chr 4:51,606,462...51,663,136
|
|
G |
Abat |
4-aminobutyrate aminotransferase |
decreases activity |
ISO |
cypermethrin results in decreased activity of ABAT protein |
CTD |
PMID:24220872 |
|
NCBI chr10:6,996,688...7,092,835
Ensembl chr10:6,999,819...7,092,835
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
decreases expression |
ISO |
cypermethrin results in decreased expression of ABCG1 mRNA |
CTD |
PMID:25424538 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Acer2 |
alkaline ceramidase 2 |
decreases expression |
ISO |
cypermethrin results in decreased expression of ACER2 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 5:101,391,830...101,442,615
Ensembl chr 5:101,391,885...101,442,614
|
|
G |
Ache |
acetylcholinesterase |
increases activity affects activity multiple interactions decreases activity |
EXP |
cypermethrin results in increased activity of ACHE protein cypermethrin affects the activity of ACHE protein [cypermethrin co-treated with fenvalerate] results in decreased activity of ACHE protein; Chlorpyrifos promotes the reaction [cypermethrin results in decreased activity of ACHE protein]; cypermethrin promotes the reaction [Chlorpyrifos results in decreased activity of ACHE protein] |
CTD |
PMID:7595515 PMID:8385837 PMID:10355540 PMID:32006337 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acot2 |
acyl-CoA thioesterase 2 |
decreases expression |
ISO |
cypermethrin results in decreased expression of ACOT2 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 6:103,611,744...103,619,404
Ensembl chr 6:103,611,544...103,619,245
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
ISO |
cypermethrin promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of ACOX1 mRNA] |
CTD |
PMID:24440342 |
|
NCBI chr10:101,406,197...101,431,242
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Adal |
adenosine deaminase-like |
increases expression |
ISO |
cypermethrin results in increased expression of ADAL mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 3:108,101,857...108,119,557
Ensembl chr 3:108,101,857...108,118,516
|
|
G |
Agt |
angiotensinogen |
affects expression multiple interactions |
EXP |
cypermethrin affects the expression of AGT Sesame Oil affects the reaction [cypermethrin affects the expression of AGT] |
CTD |
PMID:25816392 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
[prothioconazole co-treated with terbutylazine co-treated with bitertanol co-treated with cypermethrin co-treated with Malathion] results in increased activity of AHR protein; cypermethrin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein] |
CTD |
PMID:25684042 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases expression increases expression |
EXP ISO |
cypermethrin results in decreased expression of AKT1 mRNA cypermethrin results in increased expression of AKT1 mRNA |
CTD |
PMID:22528246 PMID:27704156 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
decreases expression multiple interactions increases expression |
EXP |
cypermethrin results in decreased expression of ALB mRNA Sesame Oil inhibits the reaction [cypermethrin results in increased expression of ALB] |
CTD |
PMID:9650644 PMID:11428908 PMID:25816392 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh5a1 |
aldehyde dehydrogenase 5 family, member A1 |
decreases expression |
EXP |
cypermethrin results in decreased expression of ALDH5A1 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr17:40,132,339...40,158,677
Ensembl chr17:40,130,883...40,158,677
|
|
G |
Aldh8a1 |
aldehyde dehydrogenase 8 family, member A1 |
decreases expression |
ISO |
cypermethrin results in decreased expression of ALDH8A1 mRNA |
CTD |
PMID:25424538 |
|
NCBI chr 1:16,183,940...16,203,385
Ensembl chr 1:16,183,940...16,203,385
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions increases activity |
ISO EXP |
[cypermethrin co-treated with Chlorpyrifos] results in increased expression of ALPL protein; Plant Extracts inhibits the reaction [[cypermethrin co-treated with Chlorpyrifos] results in increased expression of ALPL protein] cypermethrin inhibits the reaction [Aldosterone results in increased expression of ALPL mRNA] cypermethrin results in increased activity of ALPL protein |
CTD |
PMID:15365239 PMID:15991261 PMID:29149346 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Als2 |
alsin Rho guanine nucleotide exchange factor ALS2 |
increases expression |
ISO |
cypermethrin results in increased expression of ALS2 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 9:60,613,182...60,686,394
Ensembl chr 9:60,613,167...60,670,737
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases expression |
ISO |
cypermethrin results in increased expression of APAF1 mRNA |
CTD |
PMID:27704156 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Apc |
APC regulator of WNT signaling pathway |
increases expression |
ISO EXP |
cypermethrin results in increased expression of APC mRNA |
CTD |
PMID:21142847 PMID:22528246 |
|
NCBI chr18:25,828,558...25,925,511
Ensembl chr18:25,864,222...25,922,696
|
|
G |
Apln |
apelin |
increases expression |
ISO |
cypermethrin results in increased expression of APLN mRNA |
CTD |
PMID:29020013 |
|
NCBI chr X:127,180,801...127,213,567
Ensembl chr X:127,203,823...127,213,391
|
|
G |
Aplnr |
apelin receptor |
increases expression |
ISO |
cypermethrin results in increased expression of APLNR mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 3:70,217,407...70,221,052
Ensembl chr 3:70,217,385...70,221,050
|
|
G |
Apoa1 |
apolipoprotein A1 |
increases expression |
EXP |
cypermethrin results in increased expression of APOA1 mRNA |
CTD |
PMID:9650644 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apob |
apolipoprotein B |
increases expression |
EXP |
cypermethrin results in increased expression of APOB mRNA |
CTD |
PMID:9650644 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoe |
apolipoprotein E |
decreases expression increases expression |
EXP ISO |
cypermethrin results in decreased expression of APOE mRNA cypermethrin results in increased expression of APOE mRNA |
CTD |
PMID:9650644 PMID:11428908 PMID:21142847 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Aqr |
aquarius intron-binding spliceosomal factor |
increases expression |
ISO |
cypermethrin results in increased expression of AQR mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 3:100,874,987...100,945,026
Ensembl chr 3:100,874,987...100,945,044
|
|
G |
Ar |
androgen receptor |
multiple interactions decreases expression decreases activity |
ISO EXP |
[bitertanol co-treated with propiconazole co-treated with cypermethrin] inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; [Dihydrotestosterone co-treated with cypermethrin] results in decreased expression of AR mRNA; [terbutylazine co-treated with bitertanol co-treated with propiconazole co-treated with cypermethrin co-treated with Malathion] inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; [terbutylazine co-treated with bitertanol co-treated with propiconazole co-treated with cypermethrin co-treated with Malathion] results in decreased activity of AR protein; cypermethrin inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; cypermethrin inhibits the reaction [Metribolone results in increased activity of AR protein] [Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of AR mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of AR mRNA cypermethrin inhibits the reaction [AR protein binds to SRC protein] cypermethrin results in decreased expression of AR protein cypermethrin results in decreased expression of AR mRNA; cypermethrin results in decreased expression of AR protein cypermethrin results in decreased activity of AR protein |
CTD |
PMID:16857237 PMID:17980950 PMID:18324785 PMID:20410157 PMID:22147539 PMID:23871939 PMID:24810582 PMID:30974244 PMID:33051911 PMID:33396045 More...
|
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arg1 |
arginase 1 |
multiple interactions |
ISO |
cypermethrin promotes the reaction [Lipopolysaccharides results in increased expression of ARG1 mRNA] |
CTD |
PMID:29471534 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Armcx5 |
armadillo repeat containing, X-linked 5 |
decreases expression |
ISO |
cypermethrin results in decreased expression of ARMCX5 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr X:98,709,592...98,747,326
Ensembl chr X:98,709,841...98,714,674
|
|
G |
Atg12 |
autophagy related 12 |
increases expression |
ISO |
cypermethrin results in increased expression of ATG12 mRNA |
CTD |
PMID:27704156 |
|
NCBI chr18:39,452,247...39,462,424
Ensembl chr18:39,452,191...39,462,418
|
|
G |
Atg3 |
autophagy related 3 |
increases expression |
ISO |
cypermethrin results in increased expression of ATG3 mRNA |
CTD |
PMID:27704156 |
|
NCBI chr11:55,624,928...55,653,212
Ensembl chr11:55,624,917...55,653,224
|
|
G |
Atg5 |
autophagy related 5 |
increases expression |
ISO |
cypermethrin results in increased expression of ATG5 mRNA |
CTD |
PMID:27704156 |
|
NCBI chr20:47,798,222...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Atg7 |
autophagy related 7 |
increases expression |
ISO |
cypermethrin results in increased expression of ATG7 mRNA |
CTD |
PMID:27704156 |
|
NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593
|
|
G |
Atm |
ATM serine/threonine kinase |
increases expression |
ISO |
cypermethrin results in increased expression of ATM mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atp5mk |
ATP synthase membrane subunit k |
decreases expression |
ISO |
cypermethrin results in decreased expression of ATP5MD mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 1:245,973,910...245,980,702
Ensembl chr 1:245,973,914...245,980,761
|
|
G |
Atp5pd |
ATP synthase peripheral stalk subunit d |
decreases expression multiple interactions |
EXP |
cypermethrin results in decreased expression of ATP5H protein Minocycline inhibits the reaction [cypermethrin results in decreased expression of ATP5H protein] |
CTD |
PMID:21561882 |
|
NCBI chr10:100,657,700...100,662,960
Ensembl chr10:100,657,708...100,663,479
|
|
G |
Atp6v1f |
ATPase H+ transporting V1 subunit F |
increases expression |
EXP |
cypermethrin results in increased expression of ATP6V1F mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 4:58,067,666...58,070,628
|
|
G |
Atp6v1g2 |
ATPase H+ transporting V1 subunit G2 |
increases expression |
ISO |
cypermethrin results in increased expression of ATP6V1G2 mRNA |
CTD |
PMID:27704156 |
|
NCBI chr20:3,587,681...3,591,309
Ensembl chr20:3,587,686...3,590,481
|
|
G |
Atrx |
ATRX, chromatin remodeler |
increases expression |
ISO |
cypermethrin results in increased expression of ATRX mRNA |
CTD |
PMID:21142847 |
|
NCBI chr X:70,850,981...70,997,330
Ensembl chr X:70,850,981...70,997,330
|
|
G |
B3galt4 |
Beta-1,3-galactosyltransferase 4 |
increases expression |
ISO |
cypermethrin results in increased expression of B3GALT4 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr20:4,936,089...4,937,664
Ensembl chr20:4,931,768...4,938,315
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
increases expression |
ISO |
cypermethrin results in increased expression of BAMBI mRNA |
CTD |
PMID:29020013 |
|
NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions affects localization |
EXP ISO |
cypermethrin results in increased expression of BAX mRNA; cypermethrin results in increased expression of BAX protein Acetylcysteine inhibits the reaction [cypermethrin results in increased expression of BAX mRNA] cypermethrin affects the localization of BAX protein [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of BAX mRNA; Cyclosporine inhibits the reaction [cypermethrin affects the localization of BAX protein]; HBEGF protein inhibits the reaction [cypermethrin results in increased expression of BAX protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [cypermethrin affects the localization of BAX protein] |
CTD |
PMID:22048644 PMID:22528246 PMID:25370934 PMID:29945211 PMID:32028016 PMID:33396045 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression decreases expression |
EXP ISO |
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of BCL2 mRNA; HBEGF protein inhibits the reaction [cypermethrin results in decreased expression of BCL2 protein] cypermethrin results in increased expression of BCL2 mRNA cypermethrin results in decreased expression of BCL2 mRNA; cypermethrin results in decreased expression of BCL2 protein |
CTD |
PMID:22048644 PMID:22528246 PMID:27704156 PMID:32028016 PMID:33396045 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions increases expression decreases expression |
EXP ISO |
HBEGF protein inhibits the reaction [cypermethrin results in decreased expression of BCL2L1 protein] cypermethrin results in increased expression of BCL2L1 mRNA |
CTD |
PMID:22048644 PMID:27704156 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl6 |
BCL6, transcription repressor |
multiple interactions |
ISO |
[[[cypermethrin results in decreased expression of MIR155 mRNA] which results in increased expression of BCL6 mRNA] which results in decreased expression of MAP2K4 protein] which results in decreased phosphorylation of and results in decreased activity of MAPK8 protein; [[[cypermethrin results in decreased expression of MIR155 mRNA] which results in increased expression of BCL6 mRNA] which results in decreased expression of MAP2K4 protein] which results in decreased phosphorylation of and results in decreased activity of MAPK9 protein; [[cypermethrin results in decreased expression of MIR155 mRNA] which results in increased expression of BCL6 mRNA] which results in decreased expression of MAP2K4 protein; [cypermethrin results in decreased expression of MIR155 mRNA] which results in increased expression of BCL6 mRNA |
CTD |
PMID:29471534 |
|
NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions increases expression |
ISO EXP |
cypermethrin inhibits the reaction [Veratridine results in increased expression of BDNF mRNA] cypermethrin results in increased expression of BDNF mRNA |
CTD |
PMID:11082455 PMID:16166269 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
increases expression |
ISO |
cypermethrin results in increased expression of BIRC2 mRNA |
CTD |
PMID:27704156 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Bmf |
Bcl2 modifying factor |
increases expression |
ISO |
cypermethrin results in increased expression of BMF mRNA |
CTD |
PMID:27704156 |
|
NCBI chr 3:105,499,534...105,520,159
Ensembl chr 3:105,499,538...105,520,145
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression |
ISO |
cypermethrin results in increased expression of BNIP3 mRNA |
CTD |
PMID:32028016 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
increases expression |
EXP |
cypermethrin results in increased expression of BRAF mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
|
|
G |
Brdt |
bromodomain testis associated |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of BRDT mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of BRDT mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr14:2,421,094...2,445,842
Ensembl chr14:2,387,796...2,445,842
|
|
G |
C1galt1c1 |
C1GALT1-specific chaperone 1 |
increases expression |
ISO |
cypermethrin results in increased expression of C1GALT1C1 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr X:117,378,123...117,382,620
Ensembl chr X:117,375,525...117,382,787
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
increases expression |
ISO |
cypermethrin results in increased expression of CAMK2A mRNA |
CTD |
PMID:32028016 |
|
NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
increases expression |
ISO |
cypermethrin results in increased expression of CAMK2B mRNA |
CTD |
PMID:32028016 |
|
NCBI chr14:80,845,206...80,934,172
Ensembl chr14:80,845,238...80,933,994
|
|
G |
Casp1 |
caspase 1 |
increases expression |
EXP |
cypermethrin results in increased expression of CASP1 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases expression |
ISO EXP |
Acetylcysteine inhibits the reaction [cypermethrin results in increased activity of CASP3 protein]; Acetylcysteine inhibits the reaction [cypermethrin results in increased expression of CASP3 mRNA]; cypermethrin inhibits the reaction [Docosahexaenoic Acids results in increased cleavage of and results in increased activity of CASP3 protein] cypermethrin results in increased expression of CASP3 protein [cypermethrin co-treated with Chlorpyrifos co-treated with profenofos] results in increased cleavage of CASP3 protein cypermethrin results in increased cleavage of and results in increased activity of CASP3 protein |
CTD |
PMID:11341974 PMID:21987380 PMID:22048644 PMID:25370934 PMID:27704156 PMID:29945211 PMID:32028016 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp6 |
caspase 6 |
increases expression |
EXP |
cypermethrin results in increased expression of CASP6 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases expression |
EXP ISO |
cypermethrin results in increased cleavage of and results in increased activity of CASP7 protein cypermethrin results in increased expression of CASP7 mRNA |
CTD |
PMID:22048644 PMID:27704156 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases expression |
EXP ISO |
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of CASP9 mRNA; cypermethrin results in increased cleavage of and results in increased activity of CASP9 protein Acetylcysteine inhibits the reaction [cypermethrin results in increased expression of CASP9 mRNA] |
CTD |
PMID:22048644 PMID:22528246 PMID:27704156 PMID:29945211 PMID:33396045 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions affects binding decreases activity affects activity increases expression increases activity |
ISO EXP |
[cypermethrin co-treated with Chlorpyrifos] results in decreased activity of CAT protein; [propetamphos co-treated with cypermethrin] results in decreased activity of CAT protein; Plant Extracts inhibits the reaction [[cypermethrin co-treated with Chlorpyrifos] results in decreased activity of CAT protein] cypermethrin binds to CAT protein cypermethrin results in decreased activity of CAT protein cypermethrin affects the activity of CAT protein cypermethrin results in increased expression of CAT mRNA cypermethrin results in increased activity of CAT protein [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] affects the activity of CAT protein; [cypermethrin co-treated with fenvalerate] results in increased activity of CAT protein; [cypermethrin co-treated with propetamphos] results in decreased activity of CAT protein; Sesame Oil affects the reaction [cypermethrin affects the activity of CAT protein] |
CTD |
PMID:10355540 PMID:12965126 PMID:15365239 PMID:15991261 PMID:18214882 PMID:21142847 PMID:21397294 PMID:23900960 PMID:25816392 PMID:25926273 PMID:28584332 PMID:32214279 PMID:32278787 PMID:33396045 More...
|
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
multiple interactions |
ISO |
cypermethrin promotes the reaction [Lipopolysaccharides results in increased expression of CCL7 mRNA] |
CTD |
PMID:29471534 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G |
Ccna1 |
cyclin A1 |
decreases expression |
ISO |
cypermethrin results in decreased expression of CCNA1 mRNA |
CTD |
PMID:24810582 |
|
NCBI chr 2:139,231,738...139,278,066
Ensembl chr 2:139,201,074...139,243,157
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
EXP |
cypermethrin results in decreased expression of CCNA2 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression multiple interactions |
ISO |
cypermethrin results in increased expression of CCND1 mRNA fulvestrant inhibits the reaction [cypermethrin results in increased expression of CCND1 mRNA] |
CTD |
PMID:26877835 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
increases expression decreases expression |
EXP ISO |
cypermethrin results in increased expression of CCND2 mRNA cypermethrin results in decreased expression of CCND2 mRNA |
CTD |
PMID:22528246 PMID:24810582 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccs |
copper chaperone for superoxide dismutase |
increases expression |
ISO |
cypermethrin results in increased expression of CCS mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 1:202,113,792...202,134,931
Ensembl chr 1:202,113,804...202,134,915
|
|
G |
Cd9 |
CD9 molecule |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of CD9 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of CD9 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr 4:158,256,328...158,289,136
Ensembl chr 4:158,256,328...158,289,222
|
|
G |
Cd93 |
CD93 molecule |
increases expression |
ISO |
cypermethrin results in increased expression of CD93 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 3:135,891,859...135,898,378
Ensembl chr 3:135,891,859...135,898,378
|
|
G |
Cdh12 |
cadherin 12 |
increases expression |
EXP |
cypermethrin results in increased expression of CDH12 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 2:70,474,679...71,705,369
Ensembl chr 2:70,475,043...71,700,572
|
|
G |
Cdk9 |
cyclin-dependent kinase 9 |
decreases expression |
EXP |
cypermethrin results in decreased expression of CDK9 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 3:15,996,467...16,001,315
Ensembl chr 3:15,996,468...16,002,410
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
increases expression |
EXP |
cypermethrin results in increased expression of CDKN2B mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
|
|
G |
Cdkn2d |
cyclin dependent kinase inhibitor 2D |
decreases expression |
EXP |
cypermethrin results in decreased expression of CDKN2D mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 8:19,831,874...19,834,640
Ensembl chr 8:19,831,866...19,834,674
|
|
G |
Cebpe |
CCAAT/enhancer binding protein epsilon |
multiple interactions |
ISO |
Acetylcysteine inhibits the reaction [cypermethrin inhibits the reaction [Tretinoin results in increased expression of CEBPE mRNA]]; cypermethrin inhibits the reaction [Tretinoin results in increased expression of CEBPE mRNA] |
CTD |
PMID:29945211 |
|
NCBI chr15:28,169,885...28,171,283
Ensembl chr15:28,169,704...28,171,814
|
|
G |
Cenpa |
centromere protein A |
increases expression |
ISO |
cypermethrin results in increased expression of CENPA mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 6:25,700,142...25,711,767
Ensembl chr 6:25,700,142...25,711,675
|
|
G |
Ces1d |
carboxylesterase 1D |
increases hydrolysis |
ISO |
CES1 protein results in increased hydrolysis of cypermethrin |
CTD |
PMID:16359636 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ces2h |
carboxylesterase 2H |
increases hydrolysis |
ISO |
CES2 protein results in increased hydrolysis of cypermethrin |
CTD |
PMID:16359636 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
increases expression multiple interactions |
ISO |
cypermethrin results in increased expression of CGA mRNA 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [cypermethrin results in increased expression of CGA mRNA]; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [cypermethrin results in increased expression of CGA mRNA]; bisindolylmaleimide I inhibits the reaction [cypermethrin results in increased expression of CGA mRNA]; Egtazic Acid inhibits the reaction [cypermethrin results in increased expression of CGA mRNA]; Nimodipine inhibits the reaction [cypermethrin results in increased expression of CGA mRNA] |
CTD |
PMID:28731686 PMID:29149324 |
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Chac1 |
ChaC glutathione-specific gamma-glutamylcyclotransferase 1 |
increases expression |
ISO |
cypermethrin results in increased expression of CHAC1 mRNA |
CTD |
PMID:25424538 |
|
NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526
|
|
G |
Chat |
choline O-acetyltransferase |
decreases expression |
EXP |
cypermethrin results in decreased expression of CHAT mRNA; cypermethrin results in decreased expression of CHAT protein |
CTD |
PMID:26115703 |
|
NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093
|
|
G |
Chchd2l3 |
coiled-coil-helix-coiled-coil-helix domain containing protein 2-like 3 |
increases expression |
ISO |
cypermethrin results in increased expression of CHCHD2 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 9:94,500,439...94,501,110 NCBI chr 9:94,500,629...94,501,122
Ensembl chr 9:94,500,432...94,501,128
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
multiple interactions decreases expression |
EXP |
cypermethrin promotes the reaction [cypermethrin results in decreased expression of CHRM2 mRNA]; cypermethrin promotes the reaction [cypermethrin results in decreased expression of CHRM2 protein] cypermethrin results in decreased expression of CHRM2 mRNA; cypermethrin results in decreased expression of CHRM2 protein |
CTD |
PMID:25288152 |
|
NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103
|
|
G |
Ciita |
class II, major histocompatibility complex, transactivator |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of CIITA mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of CIITA mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr10:5,139,947...5,187,493
Ensembl chr10:5,140,178...5,187,440
|
|
G |
Cldn5 |
claudin 5 |
increases expression |
ISO |
cypermethrin results in increased expression of CLDN5 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr11:82,212,822...82,214,248
Ensembl chr11:82,211,475...82,214,992
|
|
G |
Clu |
clusterin |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of CLU mRNA |
CTD |
PMID:33051911 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Commd4 |
COMM domain containing 4 |
increases expression |
ISO |
cypermethrin results in increased expression of COMMD4 mRNA |
CTD |
PMID:27704156 |
|
NCBI chr 8:57,566,236...57,569,794
Ensembl chr 8:57,566,236...57,569,760
|
|
G |
Copg2 |
COPI coat complex subunit gamma 2 |
decreases expression |
EXP |
cypermethrin results in decreased expression of COPG2 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 4:59,366,086...59,501,591
Ensembl chr 4:59,366,086...59,501,618
|
|
G |
Cox14 |
cytochrome c oxidase assembly factor COX14 |
increases expression |
ISO |
cypermethrin results in increased expression of COX14 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 7:130,852,226...130,854,316
|
|
G |
Cox7c |
cytochrome c oxidase subunit 7C |
decreases expression |
ISO |
cypermethrin results in decreased expression of COX7C mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 2:16,841,771...16,843,796
Ensembl chr 2:16,840,837...16,843,760
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
cypermethrin promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of CPT1A mRNA] |
CTD |
PMID:24440342 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO EXP |
[cypermethrin results in decreased susceptibility to Dihydrotestosterone] which results in decreased phosphorylation of CREB1 protein [Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of CREB1 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] affects the expression of CREB1 mRNA |
CTD |
PMID:30974244 PMID:33051911 PMID:33396045 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crebbp |
CREB binding protein |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] affects the expression of CREBBP mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of CREBBP mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Crem |
cAMP responsive element modulator |
multiple interactions |
EXP |
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of CREM mRNA |
CTD |
PMID:33396045 |
|
NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989
|
|
G |
Crlf1 |
cytokine receptor-like factor 1 |
decreases expression |
EXP |
cypermethrin results in decreased expression of CRLF1 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr16:18,924,722...18,936,049
Ensembl chr16:18,924,722...18,935,997
|
|
G |
Cry2 |
cryptochrome circadian regulator 2 |
increases expression |
ISO |
cypermethrin results in increased expression of CRY2 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 3:78,374,995...78,405,001
Ensembl chr 3:78,374,995...78,404,965
|
|
G |
Csf3r |
colony stimulating factor 3 receptor |
multiple interactions |
ISO |
Acetylcysteine inhibits the reaction [cypermethrin inhibits the reaction [Tretinoin results in increased expression of CSF3R mRNA]]; cypermethrin inhibits the reaction [Tretinoin results in increased expression of CSF3R mRNA] |
CTD |
PMID:29945211 |
|
NCBI chr 5:138,298,605...138,318,224
Ensembl chr 5:138,301,506...138,317,881
|
|
G |
Ctsb |
cathepsin B |
increases expression |
ISO |
cypermethrin results in increased expression of CTSB mRNA |
CTD |
PMID:27704156 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
EXP |
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] affects the expression of CYBB mRNA |
CTD |
PMID:33396045 |
|
NCBI chr X:13,360,583...13,392,517
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization increases activity multiple interactions |
EXP |
cypermethrin affects the localization of CYCS protein cypermethrin results in increased activity of CYCS protein [propetamphos co-treated with cypermethrin] results in increased activity of CYCS protein |
CTD |
PMID:22528246 PMID:25926273 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Cygb |
cytoglobin |
increases expression |
ISO |
cypermethrin results in increased expression of CYGB mRNA |
CTD |
PMID:21142847 |
|
NCBI chr10:101,877,675...101,887,442
Ensembl chr10:101,877,676...101,887,442
|
|
G |
Cyld |
CYLD lysine 63 deubiquitinase |
increases expression |
ISO |
cypermethrin results in increased expression of CYLD mRNA |
CTD |
PMID:27704156 |
|
NCBI chr19:18,310,632...18,373,696
Ensembl chr19:18,314,019...18,373,658
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
decreases expression multiple interactions increases expression |
ISO EXP |
cypermethrin results in decreased expression of CYP11A1 mRNA [Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in increased expression of CYP11A1 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of CYP11A1 mRNA cypermethrin results in increased expression of CYP11A1 mRNA 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [cypermethrin results in increased expression of CYP11A1 mRNA]; Egtazic Acid inhibits the reaction [cypermethrin results in increased expression of CYP11A1 mRNA]; Nimodipine inhibits the reaction [cypermethrin results in increased expression of CYP11A1 mRNA] |
CTD |
PMID:20131380 PMID:21560301 PMID:24810582 PMID:28731686 PMID:33051911 PMID:33396045 More...
|
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression multiple interactions |
ISO EXP |
cypermethrin results in decreased expression of CYP17A1 mRNA; cypermethrin results in decreased expression of CYP17A1 protein [Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] affects the expression of CYP17A1 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of CYP17A1 mRNA |
CTD |
PMID:21397294 PMID:21560301 PMID:24810582 PMID:33051911 PMID:33396045 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases activity increases expression multiple interactions |
ISO EXP |
cypermethrin results in increased activity of CYP19A1 protein cypermethrin results in increased expression of CYP19A1 mRNA [Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] affects the expression of CYP19A1 mRNA; [bitertanol co-treated with propiconazole co-treated with cypermethrin co-treated with Malathion co-treated with terbutylazine] results in increased expression of CYP19A1 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] affects the expression of CYP19A1 mRNA |
CTD |
PMID:16996190 PMID:23954766 PMID:24810582 PMID:33051911 PMID:33396045 |
|
NCBI chr 8:54,553,165...54,580,758
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity affects expression increases expression |
ISO EXP |
cypermethrin results in decreased activity of CYP1A1 protein cypermethrin affects the expression of CYP1A1 mRNA cypermethrin results in increased expression of CYP1A1 mRNA |
CTD |
PMID:18420780 PMID:23447098 PMID:26115703 PMID:32214279 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity increases expression |
ISO EXP |
cypermethrin results in decreased activity of CYP1A2 protein cypermethrin results in increased expression of CYP1A2 mRNA |
CTD |
PMID:18420780 PMID:23447098 PMID:26115703 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity affects expression increases expression |
ISO |
cypermethrin results in decreased activity of CYP1B1 protein cypermethrin affects the expression of CYP1B1 mRNA cypermethrin results in increased expression of CYP1B1 |
CTD |
PMID:18420780 PMID:32214279 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp26b1 |
cytochrome P450, family 26, subfamily b, polypeptide 1 |
multiple interactions decreases expression |
ISO |
Sodium Selenite inhibits the reaction [cypermethrin results in decreased expression of CYP26B1 mRNA] |
CTD |
PMID:31659573 |
|
NCBI chr 4:117,041,808...117,058,628
Ensembl chr 4:117,041,808...117,058,628
|
|
G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
increases expression |
ISO |
cypermethrin results in increased expression of CYP2A4 mRNA |
CTD |
PMID:22310298 |
|
NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
decreases activity multiple interactions increases expression |
ISO EXP |
cypermethrin results in decreased activity of CYP2B10 protein Sodium Selenite inhibits the reaction [cypermethrin results in increased expression of CYP2B10 mRNA] cypermethrin results in increased expression of CYP2B1 mRNA |
CTD |
PMID:11377398 PMID:18420780 PMID:23447098 PMID:26115703 PMID:31659573 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
increases expression |
EXP |
cypermethrin results in increased expression of CYP2B2 mRNA |
CTD |
PMID:23447098 PMID:26115703 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases activity increases expression |
ISO |
cypermethrin results in increased activity of CYP2B6 protein cypermethrin results in increased expression of CYP2B6 mRNA; cypermethrin results in increased expression of CYP2B6 protein |
CTD |
PMID:15548381 PMID:22310298 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
increases expression |
ISO |
cypermethrin results in increased expression of CYP2C19 mRNA |
CTD |
PMID:22310298 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
increases expression decreases activity |
ISO |
cypermethrin results in increased expression of CYP2C8 mRNA cypermethrin results in decreased activity of CYP2C29 protein |
CTD |
PMID:18420780 PMID:22310298 |
|
|
|
G |
Cyp2d1 |
cytochrome P450, family 2, subfamily d, polypeptide 1 |
multiple interactions increases expression |
EXP |
cypermethrin promotes the reaction [cypermethrin results in increased expression of CYP2D1 mRNA]; cypermethrin promotes the reaction [cypermethrin results in increased expression of CYP2D1 protein] cypermethrin results in increased expression of CYP2D1 mRNA; cypermethrin results in increased expression of CYP2D1 protein |
CTD |
PMID:25288152 |
|
NCBI chr 7:113,908,950...113,913,420
Ensembl chr 7:113,908,947...113,922,084
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases activity |
ISO |
cypermethrin results in decreased activity of CYP2D6 protein |
CTD |
PMID:18420780 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity increases activity multiple interactions increases expression |
ISO EXP |
cypermethrin results in decreased activity of CYP2E1 protein cypermethrin results in increased activity of CYP2E1 protein [cypermethrin co-treated with propetamphos] results in increased activity of CYP2E1 protein cypermethrin results in increased expression of CYP2E1 mRNA; cypermethrin results in increased expression of CYP2E1 protein cypermethrin inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone] |
CTD |
PMID:18420780 PMID:20815782 PMID:22634058 PMID:23447098 PMID:25926273 PMID:26115703 More...
|
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression decreases activity increases activity |
ISO |
cypermethrin results in increased expression of CYP3A4 mRNA; cypermethrin results in increased expression of CYP3A4 protein cypermethrin results in decreased activity of CYP3A4 protein cypermethrin results in increased activity of CYP3A4 protein |
CTD |
PMID:15548381 PMID:18420780 PMID:22310298 PMID:22634058 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
multiple interactions increases expression |
EXP |
cypermethrin promotes the reaction [cypermethrin results in increased expression of CYP3A23-3A1 mRNA]; cypermethrin promotes the reaction [cypermethrin results in increased expression of CYP3A23-3A1 protein] cypermethrin results in increased expression of CYP3A23-3A1 mRNA; cypermethrin results in increased expression of CYP3A23-3A1 protein |
CTD |
PMID:25288152 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases expression multiple interactions |
ISO |
cypermethrin results in increased expression of CYP3A13 mRNA Sodium Selenite inhibits the reaction [cypermethrin results in increased expression of CYP3A13 mRNA] |
CTD |
PMID:31659573 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Dap3 |
death associated protein 3 |
increases expression |
EXP |
cypermethrin results in increased expression of DAP3 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 2:174,319,341...174,347,489
Ensembl chr 2:174,318,983...174,346,461
|
|
G |
Dazap1 |
DAZ associated protein 1 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of DAZAP1 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of DAZAP1 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr 7:9,423,673...9,448,116
Ensembl chr 7:9,424,178...9,538,818
|
|
G |
Dbi |
diazepam binding inhibitor |
decreases expression |
ISO |
cypermethrin results in decreased expression of DBI mRNA |
CTD |
PMID:29020013 |
|
NCBI chr13:31,241,466...31,249,853
Ensembl chr13:31,206,988...31,268,693
|
|
G |
Ddx25 |
DEAD-box helicase 25 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of DDX25 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of DDX25 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr 8:33,894,224...33,910,377
Ensembl chr 8:33,894,232...33,921,764
|
|
G |
Ddx3 |
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of DDX3Y mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of DDX3Y mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr Y:1,115,095...1,135,754
Ensembl chr Y:1,116,309...1,135,706
|
|
G |
Dennd4a |
DENN domain containing 4A |
increases expression |
ISO |
cypermethrin results in increased expression of DENND4A mRNA |
CTD |
PMID:27704156 |
|
NCBI chr 8:65,322,920...65,436,331
Ensembl chr 8:65,322,941...65,436,330
|
|
G |
Depp1 |
DEPP1, autophagy regulator |
decreases expression |
ISO |
cypermethrin results in decreased expression of DEPP1 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol co-treated with Sucrose co-treated with cypermethrin] results in increased expression of DGAT1 mRNA |
CTD |
PMID:24440342 |
|
NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299
|
|
G |
Dhrs9 |
dehydrogenase/reductase 9 |
decreases expression multiple interactions |
ISO |
cypermethrin results in decreased expression of DHRS9 mRNA Sodium Selenite inhibits the reaction [cypermethrin results in decreased expression of DHRS9 mRNA] |
CTD |
PMID:31659573 |
|
NCBI chr 3:54,147,834...54,170,052
Ensembl chr 3:54,147,803...54,220,241
|
|
G |
Dmrta1 |
DMRT-like family A1 |
increases expression |
ISO |
cypermethrin results in increased expression of DMRTA1 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 5:104,415,893...104,422,433
Ensembl chr 5:104,415,893...104,422,433
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] affects the expression of DNMT1 mRNA |
CTD |
PMID:33051911 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3a |
DNA methyltransferase 3 alpha |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of DNMT3A mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of DNMT3A mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of DNMT3B mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of DNMT3B mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr 3:142,130,592...142,169,124
Ensembl chr 3:142,130,592...142,169,124
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions decreases expression |
EXP |
cypermethrin inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; cypermethrin promotes the reaction [cypermethrin results in decreased expression of DRD2 mRNA]; cypermethrin promotes the reaction [cypermethrin results in decreased expression of DRD2 protein] cypermethrin results in decreased expression of DRD2 mRNA; cypermethrin results in decreased expression of DRD2 protein |
CTD |
PMID:10936494 PMID:25288152 |
|
NCBI chr 8:49,708,903...49,772,888
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Duox1 |
dual oxidase 1 |
increases expression |
ISO |
cypermethrin results in increased expression of DUOX1 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 3:109,260,526...109,295,588
Ensembl chr 3:109,262,397...109,295,563
|
|
G |
Egfr |
epidermal growth factor receptor |
affects binding multiple interactions decreases phosphorylation decreases expression |
EXP ISO |
cypermethrin binds to EGFR protein [cypermethrin results in decreased susceptibility to Dihydrotestosterone] which results in decreased phosphorylation of EGFR protein cypermethrin results in decreased phosphorylation of EGFR protein cypermethrin results in decreased expression of EGFR mRNA; cypermethrin results in decreased expression of EGFR protein |
CTD |
PMID:22048644 PMID:30974244 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions increases expression |
ISO |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [cypermethrin results in increased expression of EGR1 protein]; bisindolylmaleimide I inhibits the reaction [cypermethrin results in increased expression of EGR1 protein]; cypermethrin inhibits the reaction [Dihydrotestosterone results in increased expression of EGR1 mRNA]; cypermethrin inhibits the reaction [Dihydrotestosterone results in increased expression of EGR1 protein]; Egtazic Acid inhibits the reaction [cypermethrin results in increased expression of EGR1 protein] cypermethrin results in increased expression of EGR1 mRNA; cypermethrin results in increased expression of EGR1 protein |
CTD |
PMID:29149324 PMID:30974244 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
increases expression |
ISO |
cypermethrin results in increased expression of EIF4E mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] affects the expression of EP300 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of EP300 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases expression |
EXP |
cypermethrin results in increased expression of EPHX1 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr13:92,714,315...92,744,124
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Ercc2 |
ERCC excision repair 2, TFIIH core complex helicase subunit |
decreases expression |
EXP |
cypermethrin results in decreased expression of ERCC2 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 1:79,033,342...79,047,102
Ensembl chr 1:79,033,326...79,047,102
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
increases expression |
ISO |
cypermethrin results in increased expression of ERCC6 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions increases expression decreases expression affects binding increases activity |
ISO EXP |
cypermethrin binds to and results in increased activity of ESR1 protein; cypermethrin metabolite binds to and results in increased activity of ESR1 protein cypermethrin inhibits the reaction [Estradiol results in increased activity of ESR1 protein] cypermethrin results in increased expression of ESR1 mRNA; cypermethrin results in increased expression of ESR1 protein cypermethrin results in decreased expression of ESR1 mRNA; cypermethrin results in decreased expression of ESR1 protein cypermethrin binds to ESR1 protein cypermethrin results in increased activity of ESR1 protein |
CTD |
PMID:12396874 PMID:15064155 PMID:16395479 PMID:20397420 PMID:20574910 PMID:24388911 PMID:24810582 PMID:28531659 PMID:29253587 PMID:33049310 More...
|
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
increases expression multiple interactions |
ISO |
cypermethrin results in increased expression of ESR2 mRNA cypermethrin binds to and results in increased activity of ESR2 protein |
CTD |
PMID:20574910 PMID:33049310 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Ezh2 |
enhancer of zeste 2 polycomb repressive complex 2 subunit |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in increased expression of EZH2 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] affects the expression of EZH2 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362
|
|
G |
F3 |
coagulation factor III, tissue factor |
decreases expression |
ISO |
cypermethrin results in decreased expression of F3 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fancc |
FA complementation group C |
increases expression |
ISO |
cypermethrin results in increased expression of FANCC mRNA |
CTD |
PMID:21142847 |
|
NCBI chr17:1,680,660...1,822,610
Ensembl chr17:1,681,324...1,829,376
|
|
G |
Fancg |
FA complementation group G |
increases expression |
ISO |
cypermethrin results in increased expression of FANCG mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 5:57,230,287...57,240,067
Ensembl chr 5:57,231,685...57,240,029
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
cypermethrin results in increased expression of FAS mRNA |
CTD |
PMID:27704156 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fau |
FAU, ubiquitin like and ribosomal protein S30 fusion |
decreases expression |
ISO |
cypermethrin results in decreased expression of FAU mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 1:203,350,226...203,351,741
Ensembl chr 1:203,350,189...203,351,742
|
|
G |
Fgf5 |
fibroblast growth factor 5 |
decreases expression |
ISO |
cypermethrin results in decreased expression of FGF5 mRNA |
CTD |
PMID:32214279 |
|
NCBI chr14:11,325,334...11,346,570
Ensembl chr14:11,325,334...11,345,997
|
|
G |
Fmo2 |
flavin containing dimethylaniline monoxygenase 2 |
increases expression |
ISO |
cypermethrin results in increased expression of FMO2 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr13:75,221,149...75,244,377
Ensembl chr13:75,224,402...75,244,308
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO EXP |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [cypermethrin results in increased expression of FOS protein]; bisindolylmaleimide I inhibits the reaction [cypermethrin results in increased expression of FOS protein]; cypermethrin inhibits the reaction [Veratridine results in increased expression of FOS mRNA]; Egtazic Acid inhibits the reaction [cypermethrin results in increased expression of FOS protein] cypermethrin results in increased expression of FOS mRNA; cypermethrin results in increased expression of FOS protein |
CTD |
PMID:8856738 PMID:11082455 PMID:29149324 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Foxa2 |
forkhead box A2 |
increases expression |
ISO |
cypermethrin results in increased expression of FOXA2 mRNA |
CTD |
PMID:32214279 |
|
NCBI chr 3:135,470,123...135,474,326
Ensembl chr 3:135,470,131...135,474,326
|
|
G |
Foxf2 |
forkhead box F2 |
decreases expression |
EXP |
cypermethrin results in decreased expression of FOXF2 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr17:32,835,730...32,842,555
Ensembl chr17:32,836,777...32,842,176
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
increases expression increases secretion multiple interactions decreases expression |
EXP ISO |
cypermethrin results in increased expression of FSHB protein cypermethrin results in increased secretion of FSHB protein 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [cypermethrin results in increased expression of FSHB mRNA]; 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [cypermethrin results in increased secretion of FSHB protein]; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [cypermethrin results in increased expression of FSHB mRNA]; bisindolylmaleimide I inhibits the reaction [cypermethrin results in increased expression of FSHB mRNA]; cypermethrin results in increased expression of and results in increased secretion of FSHB protein; Egtazic Acid inhibits the reaction [cypermethrin results in increased expression of FSHB mRNA]; Egtazic Acid inhibits the reaction [cypermethrin results in increased secretion of FSHB protein]; Nimodipine inhibits the reaction [cypermethrin results in increased expression of FSHB mRNA]; Nimodipine inhibits the reaction [cypermethrin results in increased secretion of FSHB protein] Vitamin E inhibits the reaction [cypermethrin results in decreased expression of FSHB protein] |
CTD |
PMID:23447098 PMID:24759048 PMID:28731686 PMID:29149324 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] affects the expression of FSHR mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of FSHR mRNA; [cypermethrin co-treated with Diethylhexyl Phthalate] results in decreased expression of FSHR mRNA |
CTD |
PMID:24641848 PMID:33051911 PMID:33396045 |
|
NCBI chr 6:5,198,825...5,406,785
Ensembl chr 6:5,198,825...5,406,785
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions decreases activity |
EXP |
[cypermethrin co-treated with propetamphos] results in decreased activity of G6PD protein cypermethrin results in decreased activity of G6PD protein |
CTD |
PMID:25926273 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
multiple interactions decreases expression |
EXP |
cypermethrin promotes the reaction [cypermethrin results in decreased expression of GABRA1 mRNA]; cypermethrin promotes the reaction [cypermethrin results in decreased expression of GABRA1 protein] cypermethrin results in decreased expression of GABRA1 mRNA; cypermethrin results in decreased expression of GABRA1 protein |
CTD |
PMID:25288152 |
|
NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864
|
|
G |
Gabrg2 |
gamma-aminobutyric acid type A receptor subunit gamma 2 |
decreases expression |
ISO |
cypermethrin results in decreased expression of GABRG2 mRNA |
CTD |
PMID:24220872 |
|
NCBI chr10:26,376,805...26,463,680
Ensembl chr10:26,374,694...26,464,346
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
decreases expression |
EXP |
cypermethrin results in decreased expression of GAD1 mRNA; cypermethrin results in decreased expression of GAD1 protein |
CTD |
PMID:26115703 |
|
NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
EXP ISO |
cypermethrin results in increased expression of GADD45A mRNA |
CTD |
PMID:22528246 PMID:27704156 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gap43 |
growth associated protein 43 |
increases expression |
ISO |
cypermethrin results in increased expression of GAP43 mRNA |
CTD |
PMID:32028016 |
|
NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045
|
|
G |
Gata2 |
GATA binding protein 2 |
decreases expression |
EXP |
cypermethrin results in decreased expression of GATA2 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761
|
|
G |
Gata4 |
GATA binding protein 4 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] affects the expression of GATA4 mRNA |
CTD |
PMID:33051911 |
|
NCBI chr15:37,459,601...37,531,291
Ensembl chr15:37,459,601...37,505,636
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of GDNF mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of GDNF mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr 2:56,893,992...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Gfra1 |
GDNF family receptor alpha 1 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of GFRA1 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of GFRA1 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr 1:257,315,682...257,552,004
Ensembl chr 1:257,321,742...257,551,473
|
|
G |
Gh1 |
growth hormone 1 |
decreases expression |
EXP |
cypermethrin results in decreased expression of GH1 protein |
CTD |
PMID:26115703 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Gjc2 |
gap junction protein, gamma 2 |
increases expression multiple interactions |
EXP |
cypermethrin results in increased expression of GJC2 protein modified form Minocycline inhibits the reaction [cypermethrin results in increased expression of GJC2 protein modified form] |
CTD |
PMID:21561882 |
|
NCBI chr10:43,962,642...43,971,358
Ensembl chr10:43,962,642...43,970,467
|
|
G |
Glud1 |
glutamate dehydrogenase 1 |
increases expression |
ISO |
cypermethrin results in increased expression of GLUD1 mRNA |
CTD |
PMID:32573024 |
|
NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957
|
|
G |
Glul |
glutamate-ammonia ligase |
decreases activity |
ISO |
cypermethrin results in decreased activity of GLUL protein |
CTD |
PMID:24649940 |
|
NCBI chr13:65,969,064...66,035,121
Ensembl chr13:66,025,630...66,035,108
|
|
G |
Gnrh1 |
gonadotropin releasing hormone 1 |
affects secretion |
ISO |
cypermethrin affects the secretion of GNRH1 protein |
CTD |
PMID:28731686 |
|
NCBI chr15:41,972,482...41,976,690
Ensembl chr15:41,972,905...41,973,581 Ensembl chr15:41,972,905...41,973,581
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions increases secretion increases activity decreases activity |
ISO EXP |
[cypermethrin co-treated with Chlorpyrifos] results in increased expression of GOT1 protein; Plant Extracts inhibits the reaction [[cypermethrin co-treated with Chlorpyrifos] results in increased expression of GOT1 protein] cypermethrin results in increased secretion of GOT1 protein Phenobarbital inhibits the reaction [cypermethrin results in increased secretion of GOT1 protein]; Proadifen promotes the reaction [cypermethrin results in increased secretion of GOT1 protein] cypermethrin results in increased activity of GOT1 protein cypermethrin results in decreased activity of GOT1 protein |
CTD |
PMID:2466999 PMID:11428908 PMID:15365239 PMID:15991261 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Got2 |
glutamic-oxaloacetic transaminase 2 |
increases expression multiple interactions |
EXP |
cypermethrin results in increased expression of GOT2 Sesame Oil inhibits the reaction [cypermethrin results in increased expression of GOT2] |
CTD |
PMID:25816392 |
|
NCBI chr19:9,174,304...9,199,995
Ensembl chr19:9,174,311...9,199,994
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions increases expression increases activity increases secretion |
ISO EXP |
[cypermethrin co-treated with Chlorpyrifos] results in increased expression of GPT protein; Plant Extracts inhibits the reaction [[cypermethrin co-treated with Chlorpyrifos] results in increased expression of GPT protein] cypermethrin results in increased expression of GPT mRNA [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased activity of GPT protein; Phenobarbital inhibits the reaction [cypermethrin results in increased secretion of GPT protein]; Proadifen promotes the reaction [cypermethrin results in increased secretion of GPT protein]; Sesame Oil inhibits the reaction [cypermethrin results in increased expression of GPT] cypermethrin results in increased activity of GPT protein |
CTD |
PMID:11428908 PMID:15365239 PMID:15991261 PMID:25816392 PMID:32573024 PMID:33396045 More...
|
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions affects expression increases expression |
ISO |
[cypermethrin co-treated with Chlorpyrifos] results in decreased activity of GPX1 protein; Plant Extracts inhibits the reaction [[cypermethrin co-treated with Chlorpyrifos] results in decreased activity of GPX1 protein] cypermethrin affects the expression of GPX1 mRNA cypermethrin results in increased expression of GPX1 mRNA |
CTD |
PMID:15991261 PMID:21397294 PMID:32214279 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases expression |
ISO |
cypermethrin results in increased expression of GPX2 mRNA |
CTD |
PMID:21397294 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
increases expression |
ISO |
cypermethrin results in increased expression of GPX4 mRNA |
CTD |
PMID:21142847 PMID:32214279 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Grb2 |
growth factor receptor bound protein 2 |
decreases expression |
ISO |
cypermethrin results in decreased expression of GRB2 mRNA |
CTD |
PMID:27704156 |
|
NCBI chr10:100,881,404...100,949,193
Ensembl chr10:100,869,718...100,949,309
|
|
G |
Gria1 |
glutamate ionotropic receptor AMPA type subunit 1 |
affects expression |
ISO |
cypermethrin affects the expression of GRIA1 protein |
CTD |
PMID:26143737 |
|
NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
decreases expression |
EXP |
cypermethrin results in decreased expression of GRIN2A protein |
CTD |
PMID:28975519 |
|
NCBI chr10:5,630,684...6,043,341
Ensembl chr10:5,631,369...6,044,637
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
decreases expression |
EXP |
cypermethrin results in decreased expression of GRIN2B protein |
CTD |
PMID:28975519 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Grp |
gastrin releasing peptide |
increases expression |
ISO |
cypermethrin results in increased expression of GRP mRNA |
CTD |
PMID:29020013 |
|
NCBI chr18:59,388,679...59,402,061
Ensembl chr18:59,388,274...59,402,061
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions increases expression |
ISO |
[cypermethrin co-treated with Chlorpyrifos] results in decreased activity of GSR protein; Plant Extracts inhibits the reaction [[cypermethrin co-treated with Chlorpyrifos] results in decreased activity of GSR protein] cypermethrin results in increased expression of GSR mRNA |
CTD |
PMID:15991261 PMID:21142847 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
increases expression |
EXP |
cypermethrin results in increased expression of GSTA4 mRNA |
CTD |
PMID:20815782 |
|
NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
increases expression |
ISO |
cypermethrin results in increased expression of GSTA1; cypermethrin results in increased expression of GSTA1 mRNA |
CTD |
PMID:32214279 |
|
NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472
|
|
G |
Gstk1 |
glutathione S-transferase kappa 1 |
increases expression |
ISO |
cypermethrin results in increased expression of GSTK1 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 4:71,118,979...71,123,298
Ensembl chr 4:71,118,896...71,123,292
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
decreases expression |
EXP |
cypermethrin results in decreased expression of GSTP1 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gtf2h1 |
general transcription factor IIH subunit 1 |
increases expression |
ISO |
cypermethrin results in increased expression of GTF2H1 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 1:97,321,401...97,349,455
Ensembl chr 1:97,321,394...97,349,455
|
|
G |
H1f2 |
H1.2 linker histone, cluster member |
decreases expression |
ISO |
cypermethrin results in decreased expression of H1F2 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr17:41,391,106...41,392,611
Ensembl chr17:41,388,477...41,392,635
|
|
G |
Hba-a2 |
hemoglobin alpha, adult chain 2 |
decreases expression |
ISO |
cypermethrin results in decreased expression of HBA-A2 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr10:15,323,830...15,324,677
Ensembl chr10:15,307,815...15,338,392
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
multiple interactions decreases response to substance decreases expression |
EXP |
cypermethrin results in decreased expression of and results in decreased secretion of HBEGF protein; HBEGF protein inhibits the reaction [cypermethrin results in decreased expression of BCL2 protein]; HBEGF protein inhibits the reaction [cypermethrin results in decreased expression of BCL2L1 protein]; HBEGF protein inhibits the reaction [cypermethrin results in increased expression of BAX protein] HBEGF protein results in decreased susceptibility to cypermethrin cypermethrin results in decreased expression of HBEGF mRNA |
CTD |
PMID:22048644 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Hdac1 |
histone deacetylase 1 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] affects the expression of HDAC1 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of HDAC1 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
|
|
G |
Hdac10 |
histone deacetylase 10 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] affects the expression of HDAC10 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of HDAC10 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr 7:120,199,126...120,205,850
Ensembl chr 7:120,199,129...120,204,228
|
|
G |
Hdac4 |
histone deacetylase 4 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] affects the expression of HDAC4 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] affects the expression of HDAC4 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr 9:92,503,467...92,750,164
Ensembl chr 9:92,507,611...92,750,164
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
EXP |
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of HIF1A mRNA |
CTD |
PMID:33396045 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hist1h2bl |
histone cluster 1 H2B family member l |
decreases expression |
ISO |
cypermethrin results in decreased expression of H2BC7 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr17:42,708,646...42,709,435
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of HMGCR mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of HMGCR mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
decreases expression multiple interactions |
ISO EXP |
cypermethrin results in decreased expression of HMGCS1 mRNA [Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of HMGCS1 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of HMGCS1 mRNA |
CTD |
PMID:21397294 PMID:33051911 PMID:33396045 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmox1 |
heme oxygenase 1 |
affects expression decreases expression multiple interactions increases expression |
EXP ISO |
cypermethrin affects the expression of HMOX1 cypermethrin results in decreased expression of HMOX1 mRNA; cypermethrin results in decreased expression of HMOX1 protein [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of HMOX1 mRNA; Acetylcysteine inhibits the reaction [cypermethrin results in increased expression of HMOX1 mRNA]; Sesame Oil affects the reaction [cypermethrin affects the expression of HMOX1] |
CTD |
PMID:23900960 PMID:25816392 PMID:31907151 PMID:33396045 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hoxa10 |
homeobox A10 |
decreases expression |
ISO |
cypermethrin results in decreased expression of HOXA10 mRNA; cypermethrin results in decreased expression of HOXA10 protein |
CTD |
PMID:29253587 |
|
|
|
G |
Hp1bp3 |
heterochromatin protein 1, binding protein 3 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of HP1BP3 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of HP1BP3 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr 5:150,435,781...150,463,004
Ensembl chr 5:150,433,740...150,463,000
|
|
G |
Hpdl |
4-hydroxyphenylpyruvate dioxygenase-like |
increases expression |
ISO |
cypermethrin results in increased expression of HPDL mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 5:130,286,627...130,288,233
Ensembl chr 5:130,286,631...130,288,233
|
|
G |
Hrk |
harakiri, BCL2 interacting protein |
decreases expression |
ISO |
cypermethrin results in decreased expression of HRK mRNA |
CTD |
PMID:29020013 |
|
NCBI chr12:38,387,484...38,409,652
|
|
G |
Hsd17b3 |
hydroxysteroid (17-beta) dehydrogenase 3 |
decreases expression multiple interactions |
ISO EXP |
cypermethrin results in decreased expression of HSD17B3 mRNA; cypermethrin results in decreased expression of HSD17B3 protein [Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of HSD17B3 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] affects the expression of HSD17B3 mRNA |
CTD |
PMID:24810582 PMID:33051911 PMID:33396045 |
|
NCBI chr17:1,027,229...1,058,554
Ensembl chr17:1,027,229...1,058,554
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
decreases expression multiple interactions |
ISO EXP |
cypermethrin results in decreased expression of HSD3B1 mRNA; cypermethrin results in decreased expression of HSD3B1 protein [Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] affects the expression of HSD3B1 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of HSD3B1 mRNA |
CTD |
PMID:24810582 PMID:33051911 PMID:33396045 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hsf2 |
heat shock transcription factor 2 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of HSF2 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of HSF2 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr20:36,819,864...36,847,490
Ensembl chr20:36,819,864...36,850,174
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
decreases expression |
ISO |
cypermethrin results in decreased expression of HSPA5 mRNA |
CTD |
PMID:25424538 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspbap1 |
HSPB1 associated protein 1 |
increases expression |
ISO |
cypermethrin results in increased expression of HSPBAP1 mRNA |
CTD |
PMID:27704156 |
|
NCBI chr11:64,940,089...64,994,753
Ensembl chr11:64,940,091...64,994,756
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
increases expression multiple interactions |
EXP |
cypermethrin results in increased expression of HSPD1 protein Minocycline inhibits the reaction [cypermethrin results in increased expression of HSPD1 protein] |
CTD |
PMID:21561882 |
|
NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
multiple interactions increases expression |
EXP |
cypermethrin promotes the reaction [cypermethrin results in increased expression of HTR2A mRNA]; cypermethrin promotes the reaction [cypermethrin results in increased expression of HTR2A protein] cypermethrin results in increased expression of HTR2A mRNA; cypermethrin results in increased expression of HTR2A protein |
CTD |
PMID:25288152 |
|
NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Htt |
huntingtin |
increases expression |
ISO |
cypermethrin results in increased expression of HTT mRNA |
CTD |
PMID:27704156 |
|
NCBI chr14:75,845,836...75,996,094
Ensembl chr14:75,845,836...75,995,070
|
|
G |
Idh3a |
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha |
decreases expression |
EXP |
cypermethrin results in decreased expression of IDH3A protein |
CTD |
PMID:21561882 |
|
NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084
|
|
G |
Ifitm3 |
interferon induced transmembrane protein 3 |
increases expression |
ISO |
cypermethrin results in increased expression of IFITM3 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 1:196,111,026...196,112,135
Ensembl chr 1:196,111,043...196,112,203
|
|
G |
Ifng |
interferon gamma |
decreases expression |
EXP |
cypermethrin results in decreased expression of IFNG mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1 |
insulin-like growth factor 1 |
decreases expression |
EXP |
cypermethrin results in decreased expression of IGF1 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
increases expression |
ISO |
cypermethrin results in increased expression of IGF1R mRNA |
CTD |
PMID:27704156 |
|
NCBI chr 1:121,549,839...121,838,545
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Il10 |
interleukin 10 |
increases expression |
EXP |
cypermethrin results in increased expression of IL10 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il11 |
interleukin 11 |
increases expression |
EXP |
cypermethrin results in increased expression of IL11 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 1:69,069,829...69,076,129
Ensembl chr 1:69,068,137...69,076,129
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
EXP ISO |
cypermethrin results in increased expression of IL1B mRNA; cypermethrin results in increased expression of IL1B protein cypermethrin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] Acetylcysteine inhibits the reaction [cypermethrin results in increased expression of IL1B protein] |
CTD |
PMID:22528246 PMID:23900960 PMID:29471534 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
affects expression multiple interactions |
EXP |
cypermethrin affects the expression of IL6 Sesame Oil affects the reaction [cypermethrin affects the expression of IL6] |
CTD |
PMID:25816392 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il9 |
interleukin 9 |
increases expression |
EXP |
cypermethrin results in increased expression of IL9 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr17:8,111,772...8,114,895
Ensembl chr17:8,111,772...8,114,895
|
|
G |
Il9r |
interleukin 9 receptor |
increases expression |
EXP |
cypermethrin results in increased expression of IL9R mRNA |
CTD |
PMID:22528246 |
|
NCBI chr10:15,431,706...15,444,144
Ensembl chr10:15,431,706...15,441,990
|
|
G |
Ilk |
integrin-linked kinase |
decreases expression |
EXP |
cypermethrin results in decreased expression of ILK mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 1:160,088,839...160,095,140
Ensembl chr 1:160,088,897...160,095,140
|
|
G |
Ina |
internexin neuronal intermediate filament protein, alpha |
increases expression multiple interactions |
EXP |
cypermethrin results in increased expression of INA protein Minocycline inhibits the reaction [cypermethrin results in increased expression of INA protein] |
CTD |
PMID:21561882 |
|
NCBI chr 1:245,896,775...245,908,330
Ensembl chr 1:245,896,775...245,908,330
|
|
G |
Inhba |
inhibin subunit beta A |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of INHBA mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] affects the expression of INHBA mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982
|
|
G |
Inhbb |
inhibin subunit beta B |
multiple interactions decreases expression |
EXP ISO |
[cypermethrin co-treated with Diethylhexyl Phthalate] results in decreased expression of INHBB mRNA cypermethrin results in decreased expression of INHBB protein cypermethrin results in decreased expression of INHBB mRNA; cypermethrin results in decreased expression of INHBB protein |
CTD |
PMID:24641848 PMID:30974244 |
|
NCBI chr13:30,530,860...30,536,566
Ensembl chr13:30,530,860...30,537,832
|
|
G |
Insl3 |
insulin-like 3 |
decreases expression |
ISO |
cypermethrin results in decreased expression of INSL3 mRNA |
CTD |
PMID:24810582 |
|
NCBI chr16:18,398,682...18,400,566
Ensembl chr16:18,384,829...18,400,560
|
|
G |
Iqub |
IQ motif and ubiquitin domain containing |
increases expression |
ISO |
cypermethrin results in increased expression of IQUB mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 4:52,931,768...52,993,795
Ensembl chr 4:52,931,767...52,993,834
|
|
G |
Irs2 |
insulin receptor substrate 2 |
decreases expression |
EXP |
cypermethrin results in decreased expression of IRS2 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482
|
|
G |
Itgae |
integrin subunit alpha E |
decreases expression |
EXP |
cypermethrin results in decreased expression of ITGAE mRNA |
CTD |
PMID:22528246 |
|
NCBI chr10:57,704,813...57,764,093
Ensembl chr10:57,591,753...57,764,093
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
ISO |
Acetylcysteine inhibits the reaction [cypermethrin inhibits the reaction [Tretinoin results in increased expression of ITGAM mRNA]]; cypermethrin inhibits the reaction [Tretinoin results in increased expression of ITGAM mRNA] |
CTD |
PMID:29945211 |
|
NCBI chr 1:182,659,047...182,709,495
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Itgb3 |
integrin subunit beta 3 |
increases expression |
EXP |
cypermethrin results in increased expression of ITGB3 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679
|
|
G |
Itgb6 |
integrin subunit beta 6 |
increases expression |
EXP |
cypermethrin results in increased expression of ITGB6 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 3:45,046,295...45,170,532
Ensembl chr 3:45,048,044...45,121,671
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor, type 1 |
decreases expression |
EXP |
cypermethrin results in decreased expression of ITPR1 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491
|
|
G |
Jph3 |
junctophilin 3 |
increases expression |
ISO |
cypermethrin results in increased expression of JPH3 mRNA |
CTD |
PMID:27704156 |
|
NCBI chr19:49,793,967...49,855,338
Ensembl chr19:49,793,092...49,855,338
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
EXP ISO |
cypermethrin results in increased expression of JUN protein cypermethrin results in increased expression of JUN mRNA; cypermethrin results in increased expression of JUN protein 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [cypermethrin results in increased expression of JUN protein]; bisindolylmaleimide I inhibits the reaction [cypermethrin results in increased expression of JUN protein]; Egtazic Acid inhibits the reaction [cypermethrin results in increased expression of JUN protein] |
CTD |
PMID:8856738 PMID:29149324 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Jup |
junction plakoglobin |
decreases expression |
EXP |
cypermethrin results in decreased expression of JUP mRNA |
CTD |
PMID:22528246 |
|
NCBI chr10:85,300,438...85,327,378
Ensembl chr10:85,300,440...85,327,057
|
|
G |
Kcnj9 |
potassium inwardly-rectifying channel, subfamily J, member 9 |
decreases expression |
EXP |
cypermethrin results in decreased expression of KCNJ9 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr13:84,780,826...84,787,928
Ensembl chr13:84,779,741...84,787,928
|
|
G |
Kdr |
kinase insert domain receptor |
increases expression |
ISO |
cypermethrin results in increased expression of KDR mRNA |
CTD |
PMID:29020013 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Kif9 |
kinesin family member 9 |
increases expression |
ISO |
cypermethrin results in increased expression of KIF9 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 8:110,459,467...110,504,492
Ensembl chr 8:110,459,383...110,505,252
|
|
G |
Kitlg |
KIT ligand |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of KITLG mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of KITLG mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
|
|
G |
Klf2 |
Kruppel-like factor 2 |
decreases expression |
ISO |
cypermethrin results in decreased expression of KLF2 mRNA |
CTD |
PMID:25424538 |
|
NCBI chr16:17,521,773...17,523,723
Ensembl chr16:17,514,552...17,523,944
|
|
G |
Klf4 |
Kruppel like factor 4 |
multiple interactions |
EXP |
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of KLF4 mRNA |
CTD |
PMID:33396045 |
|
NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Kti12 |
KTI12 chromatin associated |
increases expression |
ISO |
cypermethrin results in increased expression of KTI12 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 5:123,601,059...123,602,581
Ensembl chr 5:123,599,436...123,613,964
|
|
G |
Kyat1 |
kynurenine aminotransferase 1 |
decreases activity |
ISO |
cypermethrin results in decreased activity of KYAT1 protein |
CTD |
PMID:7175100 |
|
NCBI chr 3:13,459,598...13,493,308
Ensembl chr 3:13,459,591...13,493,355
|
|
G |
Kynu |
kynureninase |
decreases activity |
ISO |
cypermethrin results in decreased activity of KYNU protein |
CTD |
PMID:7175100 |
|
NCBI chr 3:27,778,646...27,929,470
Ensembl chr 3:27,778,772...27,929,488
|
|
G |
Lgals7 |
galectin 7 |
decreases expression |
EXP |
cypermethrin results in decreased expression of LGALS7 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 1:84,148,612...84,152,016
Ensembl chr 1:84,150,252...84,152,015
|
|
G |
Lhb |
luteinizing hormone subunit beta |
increases expression increases secretion multiple interactions decreases expression |
EXP ISO |
cypermethrin results in increased expression of LHB protein cypermethrin results in increased secretion of LHB protein 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [cypermethrin results in increased expression of LHB mRNA]; 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [cypermethrin results in increased secretion of LHB protein]; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [cypermethrin results in increased expression of LHB mRNA]; bisindolylmaleimide I inhibits the reaction [cypermethrin results in increased expression of LHB mRNA]; cypermethrin inhibits the reaction [cetrorelix results in decreased secretion of LHB protein]; cypermethrin results in increased expression of and results in increased secretion of LHB protein; Egtazic Acid inhibits the reaction [cypermethrin results in increased expression of LHB mRNA]; Egtazic Acid inhibits the reaction [cypermethrin results in increased secretion of LHB protein]; Nimodipine inhibits the reaction [cypermethrin results in increased expression of LHB mRNA]; Nimodipine inhibits the reaction [cypermethrin results in increased secretion of LHB protein] Vitamin E inhibits the reaction [cypermethrin results in decreased expression of LHB protein] |
CTD |
PMID:23447098 PMID:24759048 PMID:28731686 PMID:29149324 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lhcgr |
luteinizing hormone/choriogonadotropin receptor |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] affects the expression of LHCGR mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of LHCGR mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr 6:5,661,871...5,728,109
Ensembl chr 6:5,661,871...5,724,521
|
|
G |
LOC102546572 |
zinc finger protein 709-like |
increases expression |
ISO |
cypermethrin results in increased expression of ZFP617 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 7:11,846,077...11,868,732
Ensembl chr 7:11,845,560...11,868,717
|
|
G |
LOC102548682 |
histone H4-like |
decreases expression |
ISO |
cypermethrin results in decreased expression of H4C14 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr17:41,368,743...41,426,735
|
|
G |
Lpp |
LIM domain containing preferred translocation partner in lipoma |
increases expression |
ISO |
cypermethrin results in increased expression of LPP mRNA |
CTD |
PMID:29020013 |
|
NCBI chr11:75,787,326...76,426,646
Ensembl chr11:75,797,078...76,422,597
|
|
G |
Ltb4r2 |
leukotriene B4 receptor 2 |
decreases expression |
ISO |
cypermethrin results in decreased expression of LTB4R2 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr15:29,258,427...29,260,340
Ensembl chr15:29,259,240...29,260,316
|
|
G |
Lysmd2 |
LysM domain containing 2 |
increases expression |
ISO |
cypermethrin results in increased expression of LYSMD2 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 8:76,378,984...76,394,395
Ensembl chr 8:76,379,219...76,394,654
|
|
G |
Maoa |
monoamine oxidase A |
decreases activity multiple interactions decreases expression |
EXP |
cypermethrin results in decreased activity of MAOA protein Chlorpyrifos promotes the reaction [cypermethrin results in decreased activity of MAOA protein]; Chlorpyrifos promotes the reaction [cypermethrin results in decreased expression of MAOA mRNA]; cypermethrin promotes the reaction [Chlorpyrifos results in decreased activity of MAOA protein]; cypermethrin promotes the reaction [Chlorpyrifos results in decreased expression of MAOA mRNA] |
CTD |
PMID:8385837 PMID:32006337 |
|
NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593
|
|
G |
Map1lc3a |
microtubule-associated protein 1 light chain 3 alpha |
increases expression |
ISO |
cypermethrin results in increased expression of MAP1LC3A mRNA |
CTD |
PMID:27704156 |
|
NCBI chr 3:143,783,024...143,784,670
Ensembl chr 3:143,783,024...143,784,670
|
|
G |
Map2 |
microtubule-associated protein 2 |
decreases expression |
EXP |
cypermethrin results in decreased expression of MAP2 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Map2k4 |
mitogen activated protein kinase kinase 4 |
multiple interactions |
ISO |
[[[cypermethrin results in decreased expression of MIR155 mRNA] which results in increased expression of BCL6 mRNA] which results in decreased expression of MAP2K4 protein] which results in decreased phosphorylation of and results in decreased activity of MAPK8 protein; [[[cypermethrin results in decreased expression of MIR155 mRNA] which results in increased expression of BCL6 mRNA] which results in decreased expression of MAP2K4 protein] which results in decreased phosphorylation of and results in decreased activity of MAPK9 protein; [[cypermethrin results in decreased expression of MIR155 mRNA] which results in increased expression of BCL6 mRNA] which results in decreased expression of MAP2K4 protein |
CTD |
PMID:29471534 |
|
NCBI chr10:50,343,227...50,447,956
Ensembl chr10:50,344,915...50,447,993
|
|
G |
Map3k4 |
mitogen activated protein kinase kinase kinase 4 |
increases expression |
EXP |
cypermethrin results in increased expression of MAP3K4 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 1:48,431,801...48,519,358
Ensembl chr 1:48,431,830...48,519,358
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [cypermethrin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; [cypermethrin results in decreased susceptibility to Dihydrotestosterone] which results in decreased phosphorylation of MAPK1 protein; bisindolylmaleimide I inhibits the reaction [cypermethrin results in increased phosphorylation of MAPK1 protein]; cypermethrin results in increased phosphorylation of and results in increased activity of MAPK1 protein; Egtazic Acid inhibits the reaction [cypermethrin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Nimodipine inhibits the reaction [cypermethrin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Thapsigargin inhibits the reaction [cypermethrin results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:29149324 PMID:30974244 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk10 |
mitogen activated protein kinase 10 |
increases expression |
ISO |
cypermethrin results in increased expression of MAPK10 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr14:6,497,662...6,790,109
Ensembl chr14:6,497,707...6,786,201
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [cypermethrin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; [cypermethrin results in decreased susceptibility to Dihydrotestosterone] which results in decreased phosphorylation of MAPK3 protein; bisindolylmaleimide I inhibits the reaction [cypermethrin results in increased phosphorylation of MAPK3 protein]; cypermethrin results in increased phosphorylation of and results in increased activity of MAPK3 protein; Egtazic Acid inhibits the reaction [cypermethrin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Nimodipine inhibits the reaction [cypermethrin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Thapsigargin inhibits the reaction [cypermethrin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; W 7 inhibits the reaction [cypermethrin results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:29149324 PMID:30974244 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk4 |
mitogen-activated protein kinase 4 |
decreases expression |
EXP |
cypermethrin results in decreased expression of MAPK4 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr18:67,512,805...67,661,271
Ensembl chr18:67,512,807...67,661,842
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases expression multiple interactions |
ISO |
cypermethrin results in increased expression of MAPK8 mRNA [[[cypermethrin results in decreased expression of MIR155 mRNA] which results in increased expression of BCL6 mRNA] which results in decreased expression of MAP2K4 protein] which results in decreased phosphorylation of and results in decreased activity of MAPK8 protein |
CTD |
PMID:27704156 PMID:29471534 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
[[[cypermethrin results in decreased expression of MIR155 mRNA] which results in increased expression of BCL6 mRNA] which results in decreased expression of MAP2K4 protein] which results in decreased phosphorylation of and results in decreased activity of MAPK9 protein |
CTD |
PMID:29471534 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mapkapk5 |
MAPK activated protein kinase 5 |
multiple interactions |
EXP |
Minocycline inhibits the reaction [cypermethrin results in increased expression of MAPKAPK5 protein] |
CTD |
PMID:21561882 |
|
NCBI chr12:34,993,520...35,013,059
Ensembl chr12:34,994,092...35,013,052
|
|
G |
Mapt |
microtubule-associated protein tau |
decreases expression increases expression |
EXP ISO |
cypermethrin results in decreased expression of MAPT mRNA cypermethrin results in increased expression of MAPT protein |
CTD |
PMID:22528246 PMID:26143737 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mb |
myoglobin |
increases expression |
ISO |
cypermethrin results in increased expression of MB mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383
|
|
G |
Mbd4 |
methyl-CpG binding domain 4 DNA glycosylase |
increases expression |
ISO |
cypermethrin results in increased expression of MBD4 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 4:148,893,049...148,904,833
Ensembl chr 4:148,894,280...148,904,982
|
|
G |
Mertk |
MER proto-oncogene, tyrosine kinase |
affects expression |
ISO |
cypermethrin affects the expression of MERTK mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 3:115,939,351...116,045,141
Ensembl chr 3:115,939,351...116,046,554
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
increases expression |
ISO |
cypermethrin results in increased expression of MGMT mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
|
|
G |
Mir155 |
microRNA 155 |
decreases expression multiple interactions |
ISO |
cypermethrin results in decreased expression of MIR155 mRNA [[[cypermethrin results in decreased expression of MIR155 mRNA] which results in increased expression of BCL6 mRNA] which results in decreased expression of MAP2K4 protein] which results in decreased phosphorylation of and results in decreased activity of MAPK8 protein; [[[cypermethrin results in decreased expression of MIR155 mRNA] which results in increased expression of BCL6 mRNA] which results in decreased expression of MAP2K4 protein] which results in decreased phosphorylation of and results in decreased activity of MAPK9 protein; [[cypermethrin results in decreased expression of MIR155 mRNA] which results in increased expression of BCL6 mRNA] which results in decreased expression of MAP2K4 protein; [cypermethrin results in decreased expression of MIR155 mRNA] which results in increased expression of BCL6 mRNA |
CTD |
PMID:29471534 |
|
NCBI chr11:23,774,654...23,774,718
Ensembl chr11:23,774,654...23,774,718
|
|
G |
Mlh1 |
mutL homolog 1 |
increases expression |
ISO |
cypermethrin results in increased expression of MLH1 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 8:111,196,468...111,233,721
Ensembl chr 8:111,196,468...111,233,617
|
|
G |
Mmp10 |
matrix metallopeptidase 10 |
multiple interactions decreases expression |
ISO |
cypermethrin promotes the reaction [Lipopolysaccharides results in increased expression of MMP10 mRNA] cypermethrin results in decreased expression of MMP10 mRNA |
CTD |
PMID:29020013 PMID:29471534 |
|
NCBI chr 8:4,689,840...4,697,748
Ensembl chr 8:4,689,840...4,697,748
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
cypermethrin promotes the reaction [Lipopolysaccharides results in increased expression of MMP9 mRNA] |
CTD |
PMID:29471534 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
increases expression |
ISO |
cypermethrin results in increased expression of MPO mRNA |
CTD |
PMID:21142847 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mpp4 |
MAGUK p55 scaffold protein 4 |
increases expression |
ISO |
cypermethrin results in increased expression of MPP4 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 9:60,569,734...60,613,035
Ensembl chr 9:60,569,734...60,611,797
|
|
G |
Mrpl14 |
mitochondrial ribosomal protein L14 |
decreases expression |
ISO |
cypermethrin results in decreased expression of MRPL14 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 9:15,302,840...15,315,195
Ensembl chr 9:15,302,427...15,315,267
|
|
G |
Mt2A |
metallothionein 2A |
increases expression decreases expression |
ISO |
cypermethrin results in increased expression of MT2 mRNA cypermethrin results in decreased expression of MT2 mRNA |
CTD |
PMID:21142847 PMID:29020013 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Nanog |
Nanog homeobox |
increases expression |
ISO |
cypermethrin results in increased expression of NANOG mRNA |
CTD |
PMID:32214279 |
|
NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116
|
|
G |
Nanos3 |
nanos C2HC-type zinc finger 3 |
decreases expression |
ISO |
cypermethrin results in decreased expression of NANOS3 mRNA |
CTD |
PMID:24810582 |
|
NCBI chr19:23,978,465...23,988,933
Ensembl chr19:23,985,504...23,988,932
|
|
G |
Nanp |
N-acetylneuraminic acid phosphatase |
decreases expression |
ISO |
cypermethrin results in decreased expression of NANP mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 3:139,826,549...139,841,655
Ensembl chr 3:139,826,549...139,841,648
|
|
G |
Ncam1 |
neural cell adhesion molecule 1 |
decreases expression |
EXP |
cypermethrin results in decreased expression of NCAM1 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 8:49,865,629...50,165,687
Ensembl chr 8:49,865,633...50,166,014
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
increases expression |
ISO |
cypermethrin results in increased expression of NCF2 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr13:64,955,502...64,986,289
Ensembl chr13:64,955,503...64,986,277
|
|
G |
Ncoa7 |
nuclear receptor coactivator 7 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of NCOA7 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of NCOA7 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr 1:26,856,228...27,016,950
Ensembl chr 1:26,856,530...27,015,871
|
|
G |
Ndufv2 |
NADH:ubiquinone oxidoreductase core subunit V2 |
decreases expression |
EXP |
cypermethrin results in decreased expression of NDUFV2 protein |
CTD |
PMID:21561882 |
|
NCBI chr 9:105,690,454...105,710,669
Ensembl chr 9:105,690,455...105,710,713
|
|
G |
Neb |
nebulin |
decreases expression |
EXP |
cypermethrin results in decreased expression of NEB mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 3:36,613,677...36,811,618
Ensembl chr 3:36,613,716...36,811,574
|
|
G |
Nefh |
neurofilament heavy chain |
increases expression |
ISO |
cypermethrin results in increased expression of NEFH mRNA |
CTD |
PMID:32028016 |
|
NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351
|
|
G |
Nefl |
neurofilament light chain |
decreases expression |
ISO |
cypermethrin results in decreased expression of NEFL mRNA |
CTD |
PMID:32028016 |
|
NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression multiple interactions decreases expression |
ISO EXP |
cypermethrin results in increased expression of NFE2L2 mRNA [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of NFE2L2 mRNA cypermethrin results in decreased expression of NFE2L2 mRNA; cypermethrin results in decreased expression of NFE2L2 protein |
CTD |
PMID:31907151 PMID:32028016 PMID:33396045 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases expression |
ISO |
cypermethrin results in increased expression of NFKB1 mRNA |
CTD |
PMID:27704156 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Ngb |
neuroglobin |
increases expression |
ISO |
cypermethrin results in increased expression of NGB mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 6:106,744,378...106,749,830
Ensembl chr 6:106,744,378...106,749,830
|
|
G |
Nhsl1 |
NHS-like 1 |
increases expression |
ISO |
cypermethrin results in increased expression of NHSL1 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 1:12,956,525...13,188,580
Ensembl chr 1:12,956,021...13,187,547
|
|
G |
Nol3 |
nucleolar protein 3 |
increases expression |
ISO |
cypermethrin results in increased expression of NOL3 mRNA |
CTD |
PMID:27704156 |
|
NCBI chr19:33,154,061...33,158,250
Ensembl chr19:33,154,062...33,158,250
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
EXP ISO |
Acetylcysteine inhibits the reaction [cypermethrin results in increased expression of NOS2 mRNA] cypermethrin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] cypermethrin results in increased expression of NOS2 mRNA; cypermethrin results in increased expression of NOS2 protein |
CTD |
PMID:22528246 PMID:23900960 PMID:29471534 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nox4 |
NADPH oxidase 4 |
increases expression |
ISO |
cypermethrin results in increased expression of NOX4 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions decreases expression |
ISO EXP |
cypermethrin results in increased expression of NQO1; cypermethrin results in increased expression of NQO1 mRNA [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of NQO1 mRNA cypermethrin results in decreased expression of NQO1 mRNA; cypermethrin results in decreased expression of NQO1 protein |
CTD |
PMID:31907151 PMID:32214279 PMID:33396045 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr0b1 |
nuclear receptor subfamily 0, group B, member 1 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of NR0B1 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of NR0B1 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr X:50,756,886...50,761,014
Ensembl chr X:50,756,886...50,761,011
|
|
G |
Nr1d1 |
nuclear receptor subfamily 1, group D, member 1 |
decreases expression |
ISO |
cypermethrin results in decreased expression of NR1D1 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr10:83,728,348...83,735,562
Ensembl chr10:83,728,318...83,735,705
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
cypermethrin inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] |
CTD |
PMID:25257666 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions increases activity increases expression |
ISO EXP |
cypermethrin binds to and results in increased activity of NR1I2 protein cypermethrin results in increased activity of NR1I2 protein cypermethrin results in increased expression of NR1I2 mRNA |
CTD |
PMID:15548381 PMID:16054614 PMID:21115097 PMID:22206814 PMID:22310298 PMID:31538121 PMID:33049310 More...
|
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions increases expression |
ISO |
cypermethrin binds to and results in increased activity of NR1I3 protein; cypermethrin inhibits the reaction [Androstane-3,17-diol binds to and results in decreased activity of NR1I3 protein] cypermethrin results in increased expression of NR1I3 mRNA |
CTD |
PMID:16929008 PMID:18832183 PMID:22310298 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
ISO |
cypermethrin inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein] |
CTD |
PMID:26647222 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
multiple interactions |
ISO |
cypermethrin inhibits the reaction [Aldosterone affects the localization of NR3C2 protein]; cypermethrin inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein] |
CTD |
PMID:29149346 |
|
NCBI chr19:30,715,648...31,059,885
Ensembl chr19:30,715,648...31,059,885
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
multiple interactions |
EXP |
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] affects the expression of NR5A1 mRNA |
CTD |
PMID:33396045 |
|
NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328
|
|
G |
Nrarp |
Notch-regulated ankyrin repeat protein |
increases expression |
ISO |
cypermethrin results in increased expression of NRARP mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 3:7,992,582...7,995,136
Ensembl chr 3:7,992,552...7,995,133
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
decreases expression |
EXP |
cypermethrin results in decreased expression of NTRK2 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136
|
|
G |
Nudt15 |
nudix hydrolase 15 |
increases expression |
ISO |
cypermethrin results in increased expression of NUDT15 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr15:48,707,776...48,747,363
Ensembl chr15:48,709,700...48,747,363
|
|
G |
Nudt18 |
nudix hydrolase 18 |
decreases expression |
ISO |
cypermethrin results in decreased expression of NUDT18 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr15:45,650,597...45,653,985
Ensembl chr15:45,650,664...45,653,963
|
|
G |
Nxph4 |
neurexophilin 4 |
increases expression |
ISO |
cypermethrin results in increased expression of NXPH4 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 7:63,367,758...63,376,579
Ensembl chr 7:63,367,761...63,376,579
|
|
G |
Olr1073 |
olfactory receptor 1073 |
increases expression |
ISO |
cypermethrin results in increased expression of OLFR1351 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 7:10,489,998...10,490,933
Ensembl chr 7:10,487,925...10,492,031
|
|
G |
Olr159 |
olfactory receptor 159 |
increases expression |
ISO |
cypermethrin results in increased expression of OLFR666 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 1:158,919,013...158,919,978
Ensembl chr 1:158,916,975...158,920,576
|
|
G |
Olr1596 |
olfactory receptor 1596 |
decreases expression |
ISO |
cypermethrin results in decreased expression of OLFR420 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr13:86,186,442...86,190,391
Ensembl chr13:86,185,529...86,190,815
|
|
G |
Olr604 |
olfactory receptor 604 |
decreases expression |
ISO |
cypermethrin results in decreased expression of OLFR1155 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 3:73,465,350...73,466,307
Ensembl chr 3:73,465,350...73,466,307
|
|
G |
Olr813 |
olfactory receptor 813 |
decreases expression |
ISO |
cypermethrin results in decreased expression of OLFR447 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 4:71,878,578...71,879,519
Ensembl chr 4:71,878,578...71,879,519
|
|
G |
Otub2 |
OTU deubiquitinase, ubiquitin aldehyde binding 2 |
increases expression |
ISO |
cypermethrin results in increased expression of OTUB2 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 6:122,545,029...122,563,651
Ensembl chr 6:122,545,061...122,563,644
|
|
G |
Ovol1 |
ovo like transcriptional repressor 1 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of OVOL1 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of OVOL1 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr 1:202,855,261...202,868,858
Ensembl chr 1:202,855,265...202,866,831
|
|
G |
P4htm |
prolyl 4-hydroxylase, transmembrane |
increases expression |
ISO |
cypermethrin results in increased expression of P4HTM mRNA |
CTD |
PMID:32573024 |
|
NCBI chr 8:109,274,629...109,292,802
Ensembl chr 8:109,274,626...109,292,473
|
|
G |
Pafah1b2 |
platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 |
decreases expression multiple interactions |
EXP |
cypermethrin results in decreased expression of PAFAH1B2 protein Minocycline inhibits the reaction [cypermethrin results in decreased expression of PAFAH1B2 protein] |
CTD |
PMID:21561882 |
|
NCBI chr 8:46,260,069...46,312,073
Ensembl chr 8:46,261,064...46,279,833
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions decreases expression |
ISO |
cypermethrin inhibits the reaction [Docosahexaenoic Acids results in increased degradation of PARP1 protein] cypermethrin results in decreased expression of PARP1 mRNA |
CTD |
PMID:11341974 PMID:27704156 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Parp2 |
poly (ADP-ribose) polymerase 2 |
increases expression |
ISO |
cypermethrin results in increased expression of PARP2 mRNA |
CTD |
PMID:27704156 |
|
NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338
|
|
G |
Pbk |
PDZ binding kinase |
increases expression |
ISO |
cypermethrin results in increased expression of PBK mRNA |
CTD |
PMID:29020013 |
|
NCBI chr15:40,022,873...40,034,014
Ensembl chr15:40,023,002...40,034,014
|
|
G |
Pcna |
proliferating cell nuclear antigen |
affects expression multiple interactions decreases expression |
ISO EXP |
cypermethrin affects the expression of PCNA mRNA; cypermethrin affects the expression of PCNA protein [Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] affects the expression of PCNA mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of PCNA mRNA cypermethrin results in decreased expression of PCNA mRNA; cypermethrin results in decreased expression of PCNA protein |
CTD |
PMID:24810582 PMID:33051911 PMID:33396045 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pde4b |
phosphodiesterase 4B |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of PDE4B mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of PDE4B mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr 5:116,799,827...117,367,707
Ensembl chr 5:116,799,971...117,367,696
|
|
G |
Pdgfa |
platelet derived growth factor subunit A |
increases expression |
EXP |
cypermethrin results in increased expression of PDGFA mRNA |
CTD |
PMID:22528246 |
|
NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497
|
|
G |
Pdia3 |
protein disulfide isomerase family A, member 3 |
decreases expression |
EXP |
cypermethrin results in decreased expression of PDIA3 protein |
CTD |
PMID:21561882 |
|
NCBI chr 3:108,388,189...108,412,013
Ensembl chr 3:108,388,245...108,413,236
|
|
G |
Pebp1 |
phosphatidylethanolamine binding protein 1 |
increases expression |
EXP |
cypermethrin results in increased expression of PEBP1 protein |
CTD |
PMID:21561882 |
|
NCBI chr12:39,302,864...39,307,064
Ensembl chr12:39,302,840...39,307,862
|
|
G |
Pgr |
progesterone receptor |
increases expression affects binding |
ISO |
cypermethrin results in increased expression of PGR mRNA; cypermethrin results in increased expression of PGR protein cypermethrin binds to PGR protein |
CTD |
PMID:29253587 PMID:32278787 |
|
NCBI chr 8:6,073,216...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Phb1 |
prohibitin 1 |
decreases expression |
EXP |
cypermethrin results in decreased expression of PHB1 protein |
CTD |
PMID:21561882 |
|
NCBI chr10:80,605,268...80,618,043
Ensembl chr10:80,605,251...80,618,042
|
|
G |
Pik3c3 |
phosphatidylinositol 3-kinase, catalytic subunit type 3 |
increases expression |
ISO |
cypermethrin results in increased expression of PIK3C3 mRNA |
CTD |
PMID:32028016 |
|
NCBI chr18:21,845,282...21,934,387
Ensembl chr18:21,845,295...21,929,048
|
|
G |
Pinx1 |
PIN2/TERF1 interacting, telomerase inhibitor 1 |
increases expression |
ISO |
cypermethrin results in increased expression of PINX1 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr15:38,098,027...38,157,143
Ensembl chr15:38,097,886...38,157,140
|
|
G |
Pklr |
pyruvate kinase L/R |
multiple interactions |
ISO |
[lard co-treated with Cholesterol co-treated with Sucrose co-treated with cypermethrin] results in increased expression of PKLR mRNA |
CTD |
PMID:24440342 |
|
NCBI chr 2:174,543,008...174,551,863
Ensembl chr 2:174,543,039...174,551,870
|
|
G |
Plekhf1 |
pleckstrin homology and FYVE domain containing 1 |
decreases expression |
ISO |
cypermethrin results in decreased expression of PLEKHF1 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 1:90,908,304...90,915,862
Ensembl chr 1:90,904,742...90,915,820
|
|
G |
Pmch |
pro-melanin-concentrating hormone |
decreases expression |
ISO |
cypermethrin results in decreased expression of PMCH mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 7:22,511,934...22,513,250
Ensembl chr 7:22,511,934...22,513,250
|
|
G |
Pms1 |
PMS1 homolog 1, mismatch repair system component |
increases expression |
ISO |
cypermethrin results in increased expression of PMS1 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 9:48,229,403...48,340,237
Ensembl chr 9:48,253,410...48,340,237
|
|
G |
Pold3 |
DNA polymerase delta 3, accessory subunit |
increases expression |
ISO |
cypermethrin results in increased expression of POLD3 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 1:154,417,893...154,456,687
Ensembl chr 1:154,418,084...154,456,665
|
|
G |
Polh |
DNA polymerase eta |
increases expression |
ISO |
cypermethrin results in increased expression of POLH mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 9:14,778,355...14,813,210
Ensembl chr 9:14,777,888...14,812,723
|
|
G |
Poli |
DNA polymerase iota |
increases expression |
ISO |
cypermethrin results in increased expression of POLI mRNA |
CTD |
PMID:21142847 |
|
NCBI chr18:64,116,774...64,134,373
Ensembl chr18:64,116,774...64,163,418
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
increases expression |
ISO |
cypermethrin results in increased expression of POU5F1 mRNA |
CTD |
PMID:32214279 |
|
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
cypermethrin promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of PPARA mRNA] |
CTD |
PMID:24440342 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
cypermethrin binds to and results in increased activity of PPARG protein |
CTD |
PMID:33049310 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppp1r15b |
protein phosphatase 1, regulatory subunit 15B |
increases expression |
ISO |
cypermethrin results in increased expression of PPP1R15B mRNA |
CTD |
PMID:21142847 |
|
NCBI chr13:44,577,840...44,585,737
Ensembl chr13:44,577,932...44,585,737
|
|
G |
Ppp3ca |
protein phosphatase 3 catalytic subunit alpha |
multiple interactions |
ISO |
[cypermethrin results in decreased activity of PPP3CA protein] which results in decreased susceptibility to Thapsigargin |
CTD |
PMID:10898953 |
|
NCBI chr 2:225,165,981...225,440,978
Ensembl chr 2:225,165,766...225,438,974
|
|
G |
Ppt1 |
palmitoyl-protein thioesterase 1 |
decreases expression |
ISO |
cypermethrin results in decreased expression of PPT1 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 5:135,121,176...135,141,076
Ensembl chr 5:135,121,163...135,142,048
|
|
G |
Prdx2 |
peroxiredoxin 2 |
increases expression |
ISO |
cypermethrin results in increased expression of PRDX2 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr19:23,180,927...23,186,217
Ensembl chr19:23,180,930...23,186,194
|
|
G |
Prdx4 |
peroxiredoxin 4 |
increases expression |
ISO |
cypermethrin results in increased expression of PRDX4 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr X:40,026,762...40,044,066
Ensembl chr X:40,026,651...40,044,066
|
|
G |
Prdx5 |
peroxiredoxin 5 |
increases expression |
ISO |
cypermethrin results in increased expression of PRDX5 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 1:204,099,826...204,103,589
Ensembl chr 1:204,099,826...204,114,268
|
|
G |
Prm1 |
protamine 1 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of PRM1 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] affects the expression of PRM1 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr10:4,871,909...4,872,155
|
|
G |
Prm2 |
protamine 2 |
multiple interactions |
EXP |
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of PRM2 mRNA |
CTD |
PMID:33396045 |
|
NCBI chr10:4,876,398...4,876,834
Ensembl chr10:4,873,372...4,877,026
|
|
G |
Prxl2a |
peroxiredoxin like 2A |
decreases expression |
ISO |
cypermethrin results in decreased expression of PRXL2A mRNA |
CTD |
PMID:29020013 |
|
NCBI chr16:16,866,601...16,886,378
Ensembl chr16:16,866,603...16,886,433
|
|
G |
Psen1 |
presenilin 1 |
increases expression |
EXP |
cypermethrin results in increased expression of PSEN1 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 6:103,323,014...103,375,088
Ensembl chr 6:103,323,120...103,371,650
|
|
G |
Psmb5 |
proteasome 20S subunit beta 5 |
increases expression |
ISO |
cypermethrin results in increased expression of PSMB5 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr15:28,072,772...28,077,367
Ensembl chr15:28,072,781...28,077,440
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[cypermethrin binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2 |
CTD |
PMID:26359731 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pygo2 |
pygopus family PHD finger 2 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of PYGO2 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of PYGO2 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr 2:174,849,670...174,854,758
Ensembl chr 2:174,849,936...174,854,758
|
|
G |
Rad51 |
RAD51 recombinase |
increases expression |
ISO |
cypermethrin results in increased expression of RAD51 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035
|
|
G |
Rad51b |
RAD51 paralog B |
increases expression |
ISO |
cypermethrin results in increased expression of RAD51B mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 6:98,096,525...98,640,988
Ensembl chr 6:98,098,868...98,640,979
|
|
G |
Rad51c |
RAD51 paralog C |
increases expression |
ISO |
cypermethrin results in increased expression of RAD51C mRNA |
CTD |
PMID:21142847 |
|
NCBI chr10:72,205,032...72,231,643
Ensembl chr10:72,205,032...72,231,248
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
ISO |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [cypermethrin results in increased phosphorylation of and results in increased activity of RAF1 protein]; bisindolylmaleimide I inhibits the reaction [cypermethrin results in increased phosphorylation of RAF1 protein]; cypermethrin promotes the reaction [[Hydrogen Peroxide co-treated with Tetradecanoylphorbol Acetate] results in increased activity of RAF1 protein]; cypermethrin results in increased phosphorylation of and results in increased activity of RAF1 protein; Egtazic Acid inhibits the reaction [cypermethrin results in increased phosphorylation of and results in increased activity of RAF1 protein]; Nimodipine inhibits the reaction [cypermethrin results in increased phosphorylation of and results in increased activity of RAF1 protein]; Thapsigargin inhibits the reaction [cypermethrin results in increased phosphorylation of and results in increased activity of RAF1 protein]; W 7 inhibits the reaction [cypermethrin results in increased phosphorylation of and results in increased activity of RAF1 protein] |
CTD |
PMID:14623285 PMID:29149324 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Rag2 |
recombination activating 2 |
increases expression |
ISO |
cypermethrin results in increased expression of RAG2 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 3:87,902,373...87,910,227
Ensembl chr 3:87,902,238...87,911,066
|
|
G |
Rdh14 |
retinol dehydrogenase 14 |
increases expression |
ISO |
cypermethrin results in increased expression of RDH14 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 6:33,156,569...33,161,712
Ensembl chr 6:33,156,569...33,161,712
|
|
G |
Retsat |
retinol saturase |
multiple interactions decreases expression |
ISO |
Sodium Selenite inhibits the reaction [cypermethrin results in decreased expression of RETSAT mRNA] |
CTD |
PMID:31659573 |
|
NCBI chr 4:104,653,306...104,662,069
Ensembl chr 4:104,653,155...104,668,310
|
|
G |
Rpl13 |
ribosomal protein L13 |
decreases expression |
ISO |
cypermethrin results in decreased expression of RPL13 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr19:51,153,990...51,156,541
Ensembl chr19:51,153,924...51,163,014
|
|
G |
Rpl15 |
ribosomal protein L15 |
decreases expression |
ISO |
cypermethrin results in decreased expression of RPL15 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr15:7,503,883...7,507,166
Ensembl chr15:7,503,883...7,507,165
|
|
G |
Rpl29 |
ribosomal protein L29 |
decreases expression |
ISO |
cypermethrin results in decreased expression of RPL29 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 8:107,068,929...107,070,963
Ensembl chr 8:107,068,480...107,070,914
|
|
G |
Rpl35 |
ribosomal protein L35 |
increases expression |
ISO |
cypermethrin results in increased expression of RPL35 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 3:22,753,255...22,756,217
Ensembl chr 3:22,753,253...22,756,243
|
|
G |
Rpl9 |
ribosomal protein L9 |
decreases expression |
ISO |
cypermethrin results in decreased expression of RPL9 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr14:42,893,945...42,897,140
Ensembl chr14:42,893,942...42,897,136
|
|
G |
Rps18 |
ribosomal protein S18 |
decreases expression |
ISO |
cypermethrin results in decreased expression of RPS18 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr20:4,931,427...4,935,538
Ensembl chr10:101,204,500...101,205,146 Ensembl chr20:101,204,500...101,205,146
|
|
G |
Rps27a |
ribosomal protein S27a |
decreases expression |
ISO |
cypermethrin results in decreased expression of RPS27A mRNA |
CTD |
PMID:29020013 |
|
NCBI chr14:103,285,734...103,288,011
Ensembl chr14:103,285,734...103,288,011
|
|
G |
Rps29 |
ribosomal protein S29 |
decreases expression |
EXP |
cypermethrin results in decreased expression of RPS29 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 6:87,635,229...87,636,605
Ensembl chr 6:87,635,230...87,636,636
|
|
G |
Rpsa |
ribosomal protein SA |
increases expression |
EXP |
cypermethrin results in increased expression of RPSA mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 8:119,851,225...119,855,103
Ensembl chr 8:119,851,225...119,855,247
|
|
G |
Scamp2 |
secretory carrier membrane protein 2 |
decreases expression |
EXP |
cypermethrin results in decreased expression of SCAMP2 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 8:57,965,612...57,992,248
Ensembl chr 8:57,965,631...57,992,646
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of SCARB1 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of SCARB1 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
[lard co-treated with Cholesterol co-treated with Sucrose co-treated with cypermethrin] results in increased expression of SCD1 mRNA |
CTD |
PMID:24440342 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Scn10a |
sodium voltage-gated channel alpha subunit 10 |
multiple interactions affects activity |
EXP |
cypermethrin affects the reaction [SCN10A protein results in increased transport of Sodium] cypermethrin affects the activity of SCN10A protein |
CTD |
PMID:16051293 PMID:19766671 |
|
NCBI chr 8:119,350,723...119,462,882
Ensembl chr 8:119,350,724...119,462,614
|
|
G |
Scn1b |
sodium voltage-gated channel beta subunit 1 |
multiple interactions |
EXP |
cypermethrin affects the reaction [[SCN2A protein binds to SCN1B protein] which results in increased transport of Sodium]; SCN1B protein promotes the reaction [cypermethrin binds to SCN2A protein] |
CTD |
PMID:9863771 PMID:18538810 |
|
NCBI chr 1:86,353,917...86,363,836
Ensembl chr 1:86,353,917...86,363,739
|
|
G |
Scn2a |
sodium voltage-gated channel alpha subunit 2 |
affects binding multiple interactions |
EXP |
cypermethrin binds to SCN2A protein cypermethrin affects the reaction [[SCN2A protein binds to SCN1B protein] which results in increased transport of Sodium]; SCN1B protein promotes the reaction [cypermethrin binds to SCN2A protein] |
CTD |
PMID:9863771 PMID:18538810 |
|
NCBI chr 3:50,302,781...50,437,504
Ensembl chr 3:50,302,877...50,437,214
|
|
G |
Scn3a |
sodium voltage-gated channel alpha subunit 3 |
multiple interactions |
EXP |
cypermethrin affects the reaction [[SCN3A protein binds to SCN3B protein] which results in increased transport of Sodium] |
CTD |
PMID:18538810 |
|
NCBI chr 3:50,146,411...50,258,119
Ensembl chr 3:50,148,139...50,258,119
|
|
G |
Scn3b |
sodium voltage-gated channel beta subunit 3 |
multiple interactions |
EXP |
cypermethrin affects the reaction [[SCN3A protein binds to SCN3B protein] which results in increased transport of Sodium] |
CTD |
PMID:18538810 |
|
NCBI chr 8:40,630,372...40,652,869
Ensembl chr 8:40,630,455...40,652,868
|
|
G |
Senp8 |
SUMO peptidase family member, NEDD8 specific |
increases expression |
ISO |
cypermethrin results in increased expression of SENP8 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 8:60,135,446...60,148,836
Ensembl chr 8:60,121,714...60,148,928
|
|
G |
Shbg |
sex hormone binding globulin |
affects binding increases expression |
ISO |
cypermethrin binds to SHBG protein cypermethrin results in increased expression of SHBG protein |
CTD |
PMID:30974244 PMID:32278787 |
|
NCBI chr10:54,332,939...54,350,409
Ensembl chr10:54,332,941...54,351,057
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of SIRT1 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of SIRT1 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc18a2 |
solute carrier family 18 member A2 |
decreases expression |
EXP |
cypermethrin results in decreased expression of SLC18A2 mRNA |
CTD |
PMID:20815782 |
|
NCBI chr 1:258,413,748...258,449,143
Ensembl chr 1:258,413,959...258,448,325
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
multiple interactions |
ISO |
cypermethrin promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of SLC2A2 mRNA] |
CTD |
PMID:24440342 |
|
NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
|
|
G |
Slc41a3 |
solute carrier family 41, member 3 |
increases expression |
ISO |
cypermethrin results in increased expression of SLC41A3 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 4:123,109,555...123,154,766
Ensembl chr 4:123,112,748...123,154,766
|
|
G |
Slc5a5 |
solute carrier family 5 member 5 |
multiple interactions |
ISO |
cypermethrin inhibits the reaction [SLC5A5 protein results in increased uptake of Iodine] |
CTD |
PMID:27979590 |
|
NCBI chr16:18,546,709...18,556,698
Ensembl chr16:18,546,709...18,556,697
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression |
ISO |
cypermethrin results in increased expression of SLC7A11 mRNA |
CTD |
PMID:25424538 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Smim12 |
small integral membrane protein 12 |
increases expression |
ISO |
cypermethrin results in increased expression of SMIM12 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 5:139,569,367...139,573,276
Ensembl chr 5:139,569,391...139,574,320
|
|
G |
Snap25 |
synaptosome associated protein 25 |
decreases expression multiple interactions |
EXP |
cypermethrin results in decreased expression of SNAP25 protein Minocycline inhibits the reaction [cypermethrin results in decreased expression of SNAP25 protein] |
CTD |
PMID:21561882 |
|
NCBI chr 3:124,041,898...124,123,761
Ensembl chr 3:124,041,898...124,123,760
|
|
G |
Snca |
synuclein alpha |
multiple interactions increases expression |
EXP ISO |
Cyclosporine inhibits the reaction [cypermethrin promotes the reaction [SNCA protein binds to SNCA protein]]; Cyclosporine inhibits the reaction [cypermethrin results in increased expression of SNCA protein]; cypermethrin promotes the reaction [SNCA protein binds to SNCA protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [cypermethrin promotes the reaction [SNCA protein binds to SNCA protein]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [cypermethrin results in increased expression of SNCA protein] cypermethrin results in increased expression of SNCA mRNA |
CTD |
PMID:25370934 PMID:27704156 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Socs2 |
suppressor of cytokine signaling 2 |
multiple interactions decreases expression |
ISO |
Sodium Selenite inhibits the reaction [cypermethrin results in decreased expression of SOCS2 mRNA] |
CTD |
PMID:31659573 |
|
NCBI chr 7:30,006,360...30,045,161
Ensembl chr 7:30,008,578...30,043,548
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions increases expression increases activity decreases activity |
ISO EXP |
[cypermethrin co-treated with Chlorpyrifos] results in decreased activity of SOD1 protein; Plant Extracts inhibits the reaction [[cypermethrin co-treated with Chlorpyrifos] results in decreased activity of SOD1 protein] cypermethrin results in increased expression of SOD1 mRNA cypermethrin results in increased activity of SOD1 protein cypermethrin results in decreased activity of SOD1 protein [cypermethrin co-treated with fenvalerate] results in increased activity of SOD1 protein |
CTD |
PMID:10355540 PMID:12965126 PMID:15365239 PMID:15991261 PMID:21397294 PMID:32214279 More...
|
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression affects expression |
ISO |
cypermethrin results in increased expression of SOD2 mRNA cypermethrin affects the expression of SOD2 mRNA |
CTD |
PMID:21142847 PMID:21397294 PMID:32214279 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in increased expression of SOX9 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] affects the expression of SOX9 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Spata2 |
spermatogenesis associated 2 |
increases expression |
ISO |
cypermethrin results in increased expression of SPATA2 mRNA |
CTD |
PMID:27704156 |
|
NCBI chr 3:156,202,962...156,213,283
Ensembl chr 3:156,202,967...156,211,705
|
|
G |
Spi1 |
Spi-1 proto-oncogene |
multiple interactions |
ISO |
Acetylcysteine inhibits the reaction [cypermethrin inhibits the reaction [Tretinoin results in increased expression of SPI1 mRNA]]; cypermethrin inhibits the reaction [Tretinoin results in increased expression of SPI1 mRNA] |
CTD |
PMID:29945211 |
|
NCBI chr 3:77,059,744...77,093,730
Ensembl chr 3:77,073,012...77,092,393
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
decreases expression |
ISO |
cypermethrin results in decreased expression of SPP1 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression |
ISO |
cypermethrin results in increased expression of SQSTM1 mRNA |
CTD |
PMID:27704156 |
|
NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
[cypermethrin results in decreased susceptibility to Dihydrotestosterone] which results in decreased phosphorylation of SRC protein; cypermethrin inhibits the reaction [AR protein binds to SRC protein] |
CTD |
PMID:30974244 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Srd5a2 |
steroid 5 alpha-reductase 2 |
increases expression |
ISO |
cypermethrin results in increased expression of SRD5A2 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 6:21,426,225...21,465,727
Ensembl chr 6:21,426,215...21,462,112
|
|
G |
Srm |
spermidine synthase |
increases expression |
ISO |
cypermethrin results in increased expression of SRM mRNA |
CTD |
PMID:32573024 |
|
NCBI chr 5:159,025,919...159,029,076
Ensembl chr 5:159,025,873...159,029,405
|
|
G |
Srxn1 |
sulfiredoxin 1 |
increases expression |
ISO |
cypermethrin results in increased expression of SRXN1 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
|
|
G |
Star |
steroidogenic acute regulatory protein |
decreases expression multiple interactions increases expression |
ISO EXP |
cypermethrin results in decreased expression of STAR mRNA; cypermethrin results in decreased expression of STAR protein [Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] affects the expression of STAR mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of STAR mRNA cypermethrin results in increased expression of STAR mRNA 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [cypermethrin results in increased expression of STAR mRNA]; Egtazic Acid inhibits the reaction [cypermethrin results in increased expression of STAR mRNA]; Nimodipine inhibits the reaction [cypermethrin results in increased expression of STAR mRNA] |
CTD |
PMID:19862501 PMID:21397294 PMID:21560301 PMID:24810582 PMID:28731686 PMID:33051911 PMID:33396045 More...
|
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stat4 |
signal transducer and activator of transcription 4 |
decreases expression multiple interactions |
EXP ISO |
cypermethrin results in decreased expression of STAT4 mRNA Sodium Selenite inhibits the reaction [cypermethrin results in decreased expression of STAT4 mRNA] |
CTD |
PMID:22528246 PMID:31659573 |
|
NCBI chr 9:49,472,660...49,588,540
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat5a |
signal transducer and activator of transcription 5A |
decreases expression |
EXP |
cypermethrin results in decreased expression of STAT5A mRNA |
CTD |
PMID:22528246 |
|
NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866
|
|
G |
Stmn1 |
stathmin 1 |
decreases expression multiple interactions |
EXP |
cypermethrin results in decreased expression of STMN1 protein Minocycline inhibits the reaction [cypermethrin results in decreased expression of STMN1 protein] |
CTD |
PMID:21561882 |
|
NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154
|
|
G |
Stra8 |
stimulated by retinoic acid 8 |
decreases expression |
ISO |
cypermethrin results in decreased expression of STRA8 mRNA |
CTD |
PMID:24810582 |
|
NCBI chr 4:63,601,443...63,624,777
Ensembl chr 4:63,601,604...63,624,771
|
|
G |
Sycp2 |
synaptonemal complex protein 2 |
increases expression |
ISO |
cypermethrin results in increased expression of SYCP2 mRNA |
CTD |
PMID:27704156 |
|
NCBI chr 3:165,431,715...165,502,134
Ensembl chr 3:165,436,331...165,498,789
|
|
G |
Syn1 |
synapsin I |
decreases expression |
ISO |
cypermethrin results in decreased expression of SYN1 mRNA |
CTD |
PMID:32028016 |
|
NCBI chr X:1,172,208...1,227,400
Ensembl chr X:1,172,208...1,227,396
|
|
G |
Taf7 |
TATA-box binding protein associated factor 7 |
increases expression |
ISO |
cypermethrin results in increased expression of TAF7 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr18:29,459,937...29,462,086
Ensembl chr18:29,452,943...29,462,134
|
|
G |
Tat |
tyrosine aminotransferase |
multiple interactions |
EXP |
cypermethrin inhibits the reaction [Hydrocortisone results in increased expression of TAT mRNA] |
CTD |
PMID:26647222 |
|
NCBI chr19:37,947,153...37,957,717
Ensembl chr19:37,947,112...37,958,031
|
|
G |
Tbxt |
T-box transcription factor T |
affects expression |
ISO |
cypermethrin affects the expression of T mRNA |
CTD |
PMID:32214279 |
|
NCBI chr 1:52,298,099...52,309,813
Ensembl chr 1:52,298,099...52,305,864
|
|
G |
Terf1 |
telomeric repeat binding factor 1 |
increases expression |
ISO |
cypermethrin results in increased expression of TERF1 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 5:3,443,103...3,472,377
Ensembl chr 5:3,443,106...3,472,340
|
|
G |
Tet1 |
tet methylcytosine dioxygenase 1 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of TET1 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of TET1 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr20:25,761,042...25,840,926
Ensembl chr20:25,768,120...25,833,052
|
|
G |
Tf |
transferrin |
increases expression |
ISO |
cypermethrin results in increased expression of TRF protein |
CTD |
PMID:30974244 |
|
NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
ISO |
cypermethrin results in increased expression of TFF1 mRNA |
CTD |
PMID:12396874 PMID:20397420 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of TGFB1 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of TGFB1 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Th |
tyrosine hydroxylase |
decreases expression |
EXP |
cypermethrin results in decreased expression of TH mRNA; cypermethrin results in decreased expression of TH protein |
CTD |
PMID:26115703 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Thy1 |
Thy-1 cell surface antigen |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of THY1 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of THY1 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr 8:44,389,495...44,394,688
Ensembl chr 8:44,389,513...44,394,659
|
|
G |
Timm10 |
translocase of inner mitochondrial membrane 10 |
increases expression |
ISO |
cypermethrin results in increased expression of TIMM10 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 3:69,908,397...69,911,943
Ensembl chr 3:69,908,456...69,911,940
|
|
G |
Timm8a1 |
translocase of inner mitochondrial membrane 8A1 |
increases expression |
ISO |
cypermethrin results in increased expression of TIMM8A1 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr X:97,717,932...97,721,918
Ensembl chr X:97,717,920...97,721,960
|
|
G |
Tmed2 |
transmembrane p24 trafficking protein 2 |
decreases expression |
EXP |
cypermethrin results in decreased expression of TMED2 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr12:32,052,542...32,061,596
Ensembl chr12:32,052,543...32,071,903
|
|
G |
Tmem74 |
transmembrane protein 74 |
increases expression |
ISO |
cypermethrin results in increased expression of TMEM74 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 7:74,929,286...74,937,973
Ensembl chr 7:74,931,694...74,937,934
|
|
G |
Tmod1 |
tropomodulin 1 |
increases expression |
ISO |
cypermethrin results in increased expression of TMOD1 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 5:60,316,445...60,393,957
Ensembl chr 5:60,338,512...60,393,956
|
|
G |
Tnf |
tumor necrosis factor |
affects expression multiple interactions increases expression |
EXP ISO |
cypermethrin affects the expression of TNF cypermethrin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] cypermethrin results in increased expression of TNF protein Acetylcysteine inhibits the reaction [cypermethrin results in increased expression of TNF protein]; Sesame Oil affects the reaction [cypermethrin affects the expression of TNF] |
CTD |
PMID:23900960 PMID:25816392 PMID:29471534 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnp1 |
transition protein 1 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of TNP1 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of TNP1 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr 9:74,594,463...74,595,072
Ensembl chr 9:74,594,466...74,595,274
|
|
G |
Tnp2 |
transition protein 2 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] affects the expression of TNP2 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of TNP2 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr10:4,879,812...4,880,540
Ensembl chr10:4,879,812...4,880,538
|
|
G |
Tp53 |
tumor protein p53 |
increases expression multiple interactions increases mutagenesis decreases expression |
EXP ISO |
cypermethrin results in increased expression of TP53 mRNA; cypermethrin results in increased expression of TP53 protein Acetylcysteine inhibits the reaction [cypermethrin results in increased expression of TP53 mRNA] cypermethrin results in increased mutagenesis of TP53 exon cypermethrin results in decreased expression of TP53 mRNA Vitamin E inhibits the reaction [cypermethrin results in increased expression of TP53 mRNA] |
CTD |
PMID:22528246 PMID:24759048 PMID:27704156 PMID:28584332 PMID:29945211 PMID:32028016 More...
|
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tph1 |
tryptophan hydroxylase 1 |
decreases expression |
EXP |
cypermethrin results in decreased expression of TPH1 mRNA; cypermethrin results in decreased expression of TPH1 protein |
CTD |
PMID:26115703 |
|
NCBI chr 1:97,157,375...97,178,415
Ensembl chr 1:97,157,409...97,178,344
|
|
G |
Trdmt1 |
tRNA aspartic acid methyltransferase 1 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] affects the expression of DNMT2 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of TRDMT1 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr17:76,601,966...76,646,104
Ensembl chr17:76,610,543...76,645,439
|
|
G |
Trex1 |
three prime repair exonuclease 1 |
increases expression |
ISO |
cypermethrin results in increased expression of TREX1 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 8:109,706,613...109,707,913
Ensembl chr 8:109,706,613...109,708,796
|
|
G |
Trmt9b |
tRNA methyltransferase 9B (putative) |
increases expression |
ISO |
cypermethrin results in increased expression of TRMT9B mRNA |
CTD |
PMID:29020013 |
|
NCBI chr16:55,740,551...55,792,198
Ensembl chr16:55,743,018...55,792,144
|
|
G |
Trpc2 |
transient receptor potential cation channel subfamily C member 2 |
increases expression |
ISO |
cypermethrin results in increased expression of TRPC2 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 1:156,460,009...156,473,039
Ensembl chr 1:156,440,305...156,473,073
|
|
G |
Trpm2 |
transient receptor potential cation channel, subfamily M, member 2 |
multiple interactions |
EXP |
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of TRPM2 mRNA |
CTD |
PMID:33396045 |
|
NCBI chr20:10,703,568...10,753,189
Ensembl chr20:10,707,014...10,753,181
|
|
G |
Tspo |
translocator protein |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] affects the expression of TSPO mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of TSPO mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr 7:114,720,188...114,730,450
Ensembl chr 7:114,720,188...114,730,450
|
|
G |
Ttc30b |
tetratricopeptide repeat domain 30B |
increases expression |
ISO |
cypermethrin results in increased expression of TTC30B mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 3:60,855,809...60,858,380
Ensembl chr 3:60,855,575...60,858,389
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
increases expression |
ISO |
cypermethrin results in increased expression of TUBB3 mRNA |
CTD |
PMID:32028016 |
|
NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243
|
|
G |
Txnip |
thioredoxin interacting protein |
increases expression decreases expression |
ISO |
cypermethrin results in increased expression of TXNIP mRNA cypermethrin results in decreased expression of TXNIP mRNA |
CTD |
PMID:21142847 PMID:29020013 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Txnl4b |
thioredoxin-like 4B |
increases expression |
ISO |
cypermethrin results in increased expression of TXNL4B mRNA |
CTD |
PMID:27704156 |
|
NCBI chr19:37,530,157...37,539,827
Ensembl chr19:37,530,152...37,538,521
|
|
G |
Txnrd2 |
thioredoxin reductase 2 |
increases expression |
ISO |
cypermethrin results in increased expression of TXNRD2 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr11:82,519,996...82,568,156
Ensembl chr11:82,519,999...82,568,156
|
|
G |
Txnrd3 |
thioredoxin reductase 3 |
increases expression |
ISO |
cypermethrin results in increased expression of TXNRD3 mRNA |
CTD |
PMID:21142847 |
|
NCBI chr 4:122,072,548...122,112,493
Ensembl chr 4:122,072,548...122,112,491
|
|
G |
Ubb |
ubiquitin B |
decreases expression |
EXP |
cypermethrin results in decreased expression of UBB mRNA |
CTD |
PMID:22528246 |
|
NCBI chr10:47,247,629...47,249,335
Ensembl chr10:47,245,637...47,249,333
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
affects expression increases expression |
ISO |
cypermethrin affects the expression of UGT1A6 mRNA cypermethrin results in increased expression of UGT1A6 |
CTD |
PMID:32214279 |
|
NCBI chr 9:88,747,229...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
increases expression |
ISO |
cypermethrin results in increased expression of ULK1 mRNA |
CTD |
PMID:27704156 |
|
NCBI chr12:45,851,710...45,877,966
Ensembl chr12:45,851,710...45,877,966
|
|
G |
Ung |
uracil-DNA glycosylase |
increases expression |
ISO |
cypermethrin results in increased expression of UNG mRNA |
CTD |
PMID:21142847 |
|
NCBI chr12:42,485,276...42,494,217
Ensembl chr12:42,485,276...42,494,206
|
|
G |
Vegfc |
vascular endothelial growth factor C |
decreases expression |
EXP |
cypermethrin results in decreased expression of VEGFC mRNA |
CTD |
PMID:22528246 |
|
NCBI chr16:37,712,408...37,827,657
Ensembl chr16:37,712,262...37,827,848
|
|
G |
Vim |
vimentin |
increases expression multiple interactions decreases expression |
ISO EXP |
cypermethrin results in increased expression of VIM mRNA [Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] affects the expression of VIM mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of VIM mRNA; [cypermethrin co-treated with Diethylhexyl Phthalate] results in decreased expression of VIM mRNA cypermethrin results in decreased expression of VIM mRNA |
CTD |
PMID:21142847 PMID:22528246 PMID:24641848 PMID:33051911 PMID:33396045 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Vldlr |
very low density lipoprotein receptor |
increases expression |
ISO |
cypermethrin results in increased expression of VLDLR mRNA |
CTD |
PMID:25424538 |
|
NCBI chr 1:224,813,539...224,850,400
Ensembl chr 1:224,814,377...224,845,920
|
|
G |
Vpreb1 |
V-set pre-B cell surrogate light chain 1 |
decreases expression |
ISO |
cypermethrin results in decreased expression of VPREB1 mRNA |
CTD |
PMID:25424538 |
|
NCBI chr11:84,126,969...84,127,846
Ensembl chr11:84,126,969...84,127,846
|
|
G |
Wnt1 |
Wnt family member 1 |
multiple interactions |
EXP |
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of WNT1 mRNA |
CTD |
PMID:33396045 |
|
NCBI chr 7:129,938,604...129,942,651
Ensembl chr 7:129,938,604...129,942,651
|
|
G |
Wnt3a |
Wnt family member 3A |
increases expression |
ISO |
cypermethrin results in increased expression of WNT3A mRNA |
CTD |
PMID:32028016 |
|
NCBI chr10:44,034,174...44,078,463
Ensembl chr10:44,034,194...44,078,324
|
|
G |
Wnt4 |
Wnt family member 4 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in increased expression of WNT4 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of WNT4 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr 5:149,513,573...149,535,415
Ensembl chr 5:149,514,018...149,532,859
|
|
G |
Wnt5a |
Wnt family member 5A |
increases expression |
ISO |
cypermethrin results in increased expression of WNT5A mRNA |
CTD |
PMID:32028016 |
|
NCBI chr16:3,695,667...3,718,234
Ensembl chr16:3,697,032...3,718,234
|
|
G |
Wnt7a |
Wnt family member 7A |
increases expression |
ISO |
cypermethrin results in increased expression of WNT7A mRNA |
CTD |
PMID:32028016 |
|
NCBI chr 4:123,863,108...123,908,981
Ensembl chr 4:123,863,108...123,908,981
|
|
G |
Wrn |
WRN RecQ like helicase |
increases expression |
ISO |
cypermethrin results in increased expression of WRN mRNA |
CTD |
PMID:21142847 |
|
NCBI chr16:58,763,517...58,898,604
Ensembl chr16:58,763,504...58,895,450
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
increases expression |
ISO |
cypermethrin results in increased expression of XIAP mRNA |
CTD |
PMID:27704156 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
G |
Xpnpep3 |
X-prolyl aminopeptidase 3 |
increases expression |
ISO |
cypermethrin results in increased expression of XPNPEP3 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 7:112,926,154...112,978,793
Ensembl chr 7:112,926,248...112,974,878
|
|
G |
Ybx1 |
Y box binding protein 1 |
increases expression |
EXP |
cypermethrin results in increased expression of YBX1 mRNA |
CTD |
PMID:22528246 |
|
NCBI chr 5:132,882,137...132,899,108
Ensembl chr 5:132,882,145...132,898,862
|
|
G |
Ybx2 |
Y box binding protein 2 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of YBX2 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] affects the expression of YBX2 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr10:54,659,719...54,665,371
Ensembl chr10:54,659,719...54,665,371
|
|
G |
Zbtb16 |
zinc finger and BTB domain containing 16 |
multiple interactions |
EXP |
[Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] affects the expression of ZBTB16 mRNA; [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of ZBTB16 mRNA |
CTD |
PMID:33051911 PMID:33396045 |
|
NCBI chr 8:48,989,376...49,177,011
Ensembl chr 8:48,994,566...49,177,011
|
|
G |
Zfp300 |
zinc finger protein 300 |
increases expression |
ISO |
cypermethrin results in increased expression of ZFP300 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr X:899,469...921,285
Ensembl chr X:913,805...918,292
|
|
G |
Zfp36l2 |
zinc finger protein 36, C3H type-like 2 |
increases expression |
ISO |
cypermethrin results in increased expression of ZFP36L2 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr 6:10,490,032...10,494,073
Ensembl chr 6:10,490,032...10,494,064
|
|
G |
Zfp709 |
zinc finger protein 709 |
increases expression |
ISO |
cypermethrin results in increased expression of ZFP709 mRNA |
CTD |
PMID:29020013 |
|
NCBI chr16:17,907,599...17,920,047
Ensembl chr16:17,909,641...17,919,700
|
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
EXP |
Methiocarb results in decreased activity of ACHE protein |
CTD |
PMID:19934164 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Alb |
albumin |
increases hydrolysis multiple interactions |
ISO EXP |
ALB protein results in increased hydrolysis of Methiocarb bis(4-nitrophenyl)phosphate inhibits the reaction [ALB protein results in increased hydrolysis of Methiocarb] |
CTD |
PMID:27665777 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO EXP |
Dihydrotestosterone inhibits the reaction [Methiocarb results in increased activity of AR protein]; Methiocarb inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]; Methiocarb inhibits the reaction [Metribolone results in increased activity of AR protein] Methiocarb inhibits the reaction [Metribolone results in increased expression of AR mRNA] |
CTD |
PMID:15064155 PMID:15519604 PMID:18324785 PMID:21310686 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions |
EXP |
[Carbaryl co-treated with Propoxur co-treated with Methiocarb co-treated with Methomyl co-treated with formetanate co-treated with oxamyl co-treated with Carbofuran] affects the activity of BCHE protein |
CTD |
PMID:22649187 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions increases metabolic processing |
ISO |
[CYP2B6 protein results in increased metabolism of Methiocarb] which results in increased abundance of methiocarb sulfoxide |
CTD |
PMID:27665777 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
increases metabolic processing multiple interactions |
ISO |
CYP2C19 protein results in increased metabolism of Methiocarb [CYP2C19 protein results in increased metabolism of Methiocarb] which results in increased abundance of methiocarb sulfoxide |
CTD |
PMID:27665777 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
increases metabolic processing multiple interactions |
ISO |
CYP2D6 protein results in increased metabolism of Methiocarb [CYP2D6 protein results in increased metabolism of Methiocarb] which results in increased abundance of methiocarb sulfoxide |
CTD |
PMID:27665777 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Esr1 |
estrogen receptor 1 |
increases activity increases expression |
ISO |
Methiocarb results in increased activity of ESR1 protein Methiocarb results in increased expression of ESR1 protein |
CTD |
PMID:15064155 PMID:19206145 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
increases activity increases expression |
ISO |
Methiocarb results in increased activity of ESR2 protein Methiocarb results in increased expression of ESR2 mRNA |
CTD |
PMID:15064155 PMID:15130599 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fmo1 |
flavin containing dimethylaniline monoxygenase 1 |
multiple interactions increases metabolic processing |
ISO |
[FMO1 protein results in increased metabolism of Methiocarb] which results in increased abundance of methiocarb sulfoxide |
CTD |
PMID:27665777 |
|
NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647
|
|
G |
Il2 |
interleukin 2 |
decreases response to substance |
ISO |
Methiocarb results in decreased susceptibility to IL2 protein |
CTD |
PMID:8349949 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Lhb |
luteinizing hormone subunit beta |
decreases expression |
EXP |
Methiocarb results in decreased expression of LHB protein |
CTD |
PMID:15519604 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
EXP |
Methiocarb results in increased activity of NR1I2 protein |
CTD |
PMID:27665777 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
decreases expression |
EXP |
Methiocarb results in decreased expression of ODC1 mRNA |
CTD |
PMID:15519604 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases activity |
EXP |
Methiocarb results in increased activity of PPARA protein |
CTD |
PMID:27665777 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[Methiocarb binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2 |
CTD |
PMID:26359731 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Scgb2a1 |
secretoglobin, family 2A, member 1 |
decreases expression |
EXP |
Methiocarb results in decreased expression of SCGB2A2 mRNA |
CTD |
PMID:15519604 |
|
NCBI chr 1:206,497,848...206,501,211
Ensembl chr 1:206,497,849...206,501,211 Ensembl chr 1:206,497,849...206,501,211
|
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
decreases expression |
ISO |
Niclosamide results in decreased expression of ACACA mRNA |
CTD |
PMID:22576131 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA] Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of ACP5 mRNA] |
CTD |
PMID:26792726 PMID:28824321 |
|
NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ACSL1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [Doxorubicin results in increased expression of ACTA2 protein] Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of ACTA2 protein] |
CTD |
PMID:26643609 PMID:28318631 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adh4 |
alcohol dehydrogenase 4 (class II), pi polypeptide |
decreases expression |
ISO |
Niclosamide results in decreased expression of ADH4 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591
|
|
G |
Afp |
alpha-fetoprotein |
multiple interactions |
EXP |
Niclosamide inhibits the reaction [Thioacetamide results in increased expression of AFP protein]; Poloxamer promotes the reaction [Niclosamide inhibits the reaction [Thioacetamide results in increased expression of AFP protein]] |
CTD |
PMID:32961231 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases cleavage |
ISO |
Niclosamide results in increased cleavage of AIFM1 protein |
CTD |
PMID:22576131 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases expression multiple interactions |
ISO |
Niclosamide results in increased expression of AKT1 mRNA Niclosamide inhibits the reaction [TNF protein results in increased activity of AKT1 protein]; Niclosamide inhibits the reaction [TNFSF11 protein results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:20215516 PMID:26792726 PMID:29843133 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ALDH1A1 protein |
CTD |
PMID:24736023 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldob |
aldolase, fructose-bisphosphate B |
increases expression |
ISO |
Niclosamide results in increased expression of ALDOB mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 5:63,889,045...63,902,086
Ensembl chr 5:63,889,046...63,902,116
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
decreases expression |
ISO |
Niclosamide results in decreased expression of ALDOC mRNA |
CTD |
PMID:22576131 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Alox12b |
arachidonate 12-lipoxygenase, 12R type |
increases expression multiple interactions decreases response to substance |
ISO |
Niclosamide results in increased expression of ALOX12B mRNA TP53 gene mutant form inhibits the reaction [Niclosamide results in increased expression of ALOX12B mRNA]; TP53 protein mutant form inhibits the reaction [Niclosamide results in increased expression of ALOX12B mRNA] ALOX12B protein results in decreased susceptibility to Niclosamide |
CTD |
PMID:30258081 |
|
NCBI chr10:53,863,060...53,874,938
Ensembl chr10:53,863,060...53,874,938
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions decreases response to substance increases expression |
ISO |
TP53 gene mutant form inhibits the reaction [Niclosamide results in increased expression of ALOX5 mRNA]; TP53 protein mutant form inhibits the reaction [Niclosamide results in increased expression of ALOX5 mRNA] ALOX5 protein results in decreased susceptibility to Niclosamide |
CTD |
PMID:30258081 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
decreases expression |
ISO |
Niclosamide results in decreased expression of ALPL mRNA |
CTD |
PMID:28824321 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Apof |
apolipoprotein F |
decreases expression |
ISO |
Niclosamide results in decreased expression of APOF mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 7:700,688...702,130
Ensembl chr 7:700,762...701,946
|
|
G |
Ar |
androgen receptor |
multiple interactions decreases expression |
ISO |
[enzalutamide co-treated with Niclosamide] results in decreased expression of AR protein; [Niclosamide inhibits the reaction [AR protein binds to KLK3 promoter]] which results in decreased expression of KLK3 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Niclosamide results in decreased expression of and results in increased degradation of AR protein alternative form]; bicalutamide promotes the reaction [Niclosamide inhibits the reaction [AR protein binds to KLK3 promoter]]; bicalutamide promotes the reaction [Niclosamide results in decreased expression of AR protein alternative form]; bicalutamide promotes the reaction [Niclosamide results in decreased expression of AR protein]; Niclosamide inhibits the reaction [AR protein alternative form binds to KLK3 promoter]; Niclosamide inhibits the reaction [AR protein alternative form results in decreased susceptibility to enzalutamide]; Niclosamide inhibits the reaction [AR protein alternative form results in increased expression of KLK3 mRNA]; Niclosamide inhibits the reaction [AR protein alternative form results in increased expression of KLK3 protein]; Niclosamide inhibits the reaction [AR protein binds to KLK3 promoter]; Niclosamide inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]; Niclosamide results in decreased expression of and results in increased degradation of AR protein alternative form Niclosamide results in decreased expression of AR protein; Niclosamide results in decreased expression of AR protein alternative form |
CTD |
PMID:24740322 PMID:25970160 PMID:28500234 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Araf |
A-Raf proto-oncogene, serine/threonine kinase |
decreases expression |
ISO |
Niclosamide analog results in decreased expression of ARAF protein; Niclosamide results in decreased expression of ARAF protein |
CTD |
PMID:28284560 |
|
NCBI chr X:1,227,392...1,292,356
Ensembl chr X:1,227,392...1,239,073
|
|
G |
Asf1b |
anti-silencing function 1B histone chaperone |
decreases expression |
ISO |
Niclosamide results in decreased expression of ASF1B mRNA |
CTD |
PMID:28284560 |
|
NCBI chr19:24,181,024...24,195,604
Ensembl chr19:24,181,028...24,195,549
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression multiple interactions |
ISO |
Niclosamide results in increased expression of ATF3 mRNA; Niclosamide results in increased expression of ATF3 protein ATF3 protein affects the reaction [Niclosamide results in increased cleavage of CASP3 protein]; ATF3 protein affects the reaction [Niclosamide results in increased expression of DDIT3 mRNA]; ATF3 protein affects the reaction [Niclosamide results in increased expression of EIF2AK3 mRNA] |
CTD |
PMID:26917416 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression |
ISO |
Niclosamide results in increased expression of ATF4 mRNA; Niclosamide results in increased expression of ATF4 protein |
CTD |
PMID:26917416 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atp5f1a |
ATP synthase F1 subunit alpha |
increases expression |
ISO |
Niclosamide results in increased expression of ATP5F1A mRNA |
CTD |
PMID:22576131 |
|
NCBI chr18:71,292,406...71,300,342
Ensembl chr18:71,292,374...71,300,794
|
|
G |
Atp5f1d |
ATP synthase F1 subunit delta |
increases expression |
ISO |
Niclosamide results in increased expression of ATP5F1D mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 7:9,560,604...9,565,919
Ensembl chr 7:9,560,608...9,565,929
|
|
G |
Atp5mc3 |
ATP synthase membrane subunit c locus 3 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ATP5MC3 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 3:58,810,535...58,813,185
Ensembl chr 3:58,810,535...58,814,279
|
|
G |
Atp5mf |
ATP synthase membrane subunit f |
decreases expression |
ISO |
Niclosamide results in decreased expression of ATP5MF mRNA |
CTD |
PMID:22576131 |
|
NCBI chr12:9,421,665...9,428,236
Ensembl chr12:9,421,579...9,428,236
|
|
G |
Atp5mg |
ATP synthase membrane subunit g |
decreases expression |
ISO |
Niclosamide results in decreased expression of ATP5MG mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 8:45,226,750...45,233,582
Ensembl chr 8:45,225,686...45,233,559
|
|
G |
Atp5pb |
ATP synthase peripheral stalk-membrane subunit b |
decreases expression |
ISO |
Niclosamide results in decreased expression of ATP5PB mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 2:193,424,138...193,435,418
Ensembl chr 2:193,424,047...193,435,418
|
|
G |
Atp6ap1 |
ATPase H+ transporting accessory protein 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ATP6AP1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr X:152,079,954...152,087,034
Ensembl chr X:152,079,865...152,087,034
|
|
G |
Atp6v0d2 |
ATPase H+ transporting V0 subunit D2 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of ATP6V0D2 mRNA] |
CTD |
PMID:26792726 |
|
NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:33,336,264...33,385,354
|
|
G |
Aurkb |
aurora kinase B |
decreases expression |
ISO |
Niclosamide results in decreased expression of AURKB mRNA |
CTD |
PMID:28284560 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Axin2 |
axin 2 |
multiple interactions decreases expression |
ISO |
Niclosamide inhibits the reaction [Lithium Chloride results in increased expression of AXIN2 mRNA] Niclosamide results in decreased expression of AXIN2 mRNA; Niclosamide results in decreased expression of AXIN2 protein |
CTD |
PMID:22576131 PMID:24534281 PMID:24552774 PMID:24736023 |
|
NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
ISO |
[Niclosamide binds to Polyethyleneimine] which results in increased expression of BAD mRNA |
CTD |
PMID:25988281 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions |
ISO |
[Niclosamide binds to Polyethyleneimine] which results in increased expression of BAK1 mRNA |
CTD |
PMID:25988281 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions decreases expression |
ISO |
Niclosamide results in increased expression of BAX protein [Niclosamide binds to Polyethyleneimine] which results in increased expression of BAX mRNA; [Niclosamide co-treated with bicalutamide] results in increased expression of BAX protein; bicalutamide inhibits the reaction [Niclosamide results in decreased expression of BAX protein] |
CTD |
PMID:25634333 PMID:25988281 PMID:26703449 PMID:28500234 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions increases expression |
ISO |
TP53 gene mutant form inhibits the reaction [Niclosamide results in increased expression of BBC3 mRNA] |
CTD |
PMID:30258081 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO |
Niclosamide analog results in decreased expression of BCL2 protein; Niclosamide results in decreased expression of BCL2 protein [Niclosamide binds to Polyethyleneimine] which results in decreased expression of BCL2 mRNA; [Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; bicalutamide promotes the reaction [Niclosamide results in decreased expression of BCL2 protein]; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2 protein]; Niclosamide inhibits the reaction [TNF protein results in increased expression of BCL2 mRNA]; Niclosamide promotes the reaction [bicalutamide results in decreased expression of BCL2 protein] |
CTD |
PMID:20215516 PMID:23894143 PMID:25634333 PMID:25988281 PMID:26116531 PMID:26703449 PMID:28284560 PMID:28500234 More...
|
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions decreases expression |
ISO |
[Niclosamide binds to Polyethyleneimine] which results in decreased expression of BCL2L1 mRNA; bicalutamide promotes the reaction [Niclosamide results in decreased expression of BCL2L1 protein]; Niclosamide inhibits the reaction [TNF protein results in increased expression of BCL2L1 mRNA]; Niclosamide promotes the reaction [bicalutamide results in decreased expression of BCL2L1 protein] Niclosamide analog results in decreased expression of BCL2L1 protein; Niclosamide results in decreased expression of BCL2L1 protein |
CTD |
PMID:20215516 PMID:25988281 PMID:26116531 PMID:28284560 PMID:28500234 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl2l2 |
Bcl2-like 2 |
decreases expression multiple interactions |
ISO |
Niclosamide results in decreased expression of BCL2L2 protein [Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L2 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L2 protein] |
CTD |
PMID:23894143 |
|
NCBI chr15:28,346,449...28,361,627
Ensembl chr15:28,356,807...28,361,624
|
|
G |
Bcl6 |
BCL6, transcription repressor |
multiple interactions |
ISO |
Niclosamide affects the reaction [FAS protein mutant form affects the expression of BCL6 mRNA]; Niclosamide affects the reaction [FAS protein mutant form affects the expression of BCL6 protein] |
CTD |
PMID:33632240 |
|
NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389
|
|
G |
Bcl9 |
BCL9, transcription coactivator |
decreases expression |
EXP |
Niclosamide results in decreased expression of BCL9 mRNA |
CTD |
PMID:27338550 |
|
NCBI chr 2:184,760,616...184,846,261
Ensembl chr 2:184,760,618...184,786,435
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions affects expression decreases expression |
ISO |
enzalutamide promotes the reaction [Niclosamide results in decreased expression of BIRC5 protein]; Niclosamide inhibits the reaction [IL6 protein results in increased expression of BIRC5 protein] Niclosamide affects the expression of BIRC5 protein Niclosamide analog results in decreased expression of BIRC5 protein; Niclosamide results in decreased expression of BIRC5 protein |
CTD |
PMID:24552774 PMID:24736023 PMID:25970160 PMID:28284560 PMID:28500234 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
decreases expression decreases phosphorylation |
ISO |
Niclosamide analog results in decreased expression of BRAF protein; Niclosamide results in decreased expression of BRAF protein Niclosamide analog results in decreased phosphorylation of BRAF protein |
CTD |
PMID:28284560 |
|
NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
[Niclosamide co-treated with Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CASP1 protein Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein] |
CTD |
PMID:33524445 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions increases expression decreases expression |
ISO EXP |
Niclosamide results in increased cleavage of CASP3 protein Niclosamide inhibits the reaction [Thioacetamide results in decreased expression of CASP3 mRNA]; Poloxamer promotes the reaction [Niclosamide inhibits the reaction [Thioacetamide results in decreased expression of CASP3 mRNA]] [TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased expression of CASP3 protein modified form; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 protein modified form] Niclosamide results in increased expression of CASP3 protein modified form Niclosamide results in decreased expression of CASP3 protein 7-methyl-5-(1-((3-(trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine inhibits the reaction [Niclosamide results in increased cleavage of CASP3 protein]; [Niclosamide binds to Polyethyleneimine] which results in increased expression of CASP3 mRNA; ATF3 protein affects the reaction [Niclosamide results in increased cleavage of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [Niclosamide results in increased cleavage of CASP3 protein]; TP53 gene mutant form promotes the reaction [Niclosamide results in increased cleavage of CASP3 protein]; WNT7A protein affects the reaction [Niclosamide results in increased cleavage of CASP3 protein] |
CTD |
PMID:20215516 PMID:21871175 PMID:24750999 PMID:25174399 PMID:25634333 PMID:25988281 PMID:26116531 PMID:26703449 PMID:26917416 PMID:28824321 PMID:29031202 PMID:30258081 PMID:30329025 PMID:32961231 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases expression |
ISO |
bicalutamide promotes the reaction [Niclosamide results in increased expression of CASP7 protein modified form] |
CTD |
PMID:26116531 PMID:28500234 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases expression increases cleavage |
ISO |
TP53 gene mutant form promotes the reaction [Niclosamide results in increased cleavage of CASP9 protein] Niclosamide results in increased expression of CASP9 protein modified form |
CTD |
PMID:26116531 PMID:26703449 PMID:30258081 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO EXP |
Niclosamide inhibits the reaction [Doxorubicin results in increased expression of CCL2 mRNA]; Niclosamide inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein] Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of CCL2 mRNA] |
CTD |
PMID:24561310 PMID:28318631 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
multiple interactions |
ISO EXP |
Niclosamide inhibits the reaction [Doxorubicin results in increased expression of CCL20 mRNA] Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of CCL20 mRNA] |
CTD |
PMID:28318631 |
|
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein] |
CTD |
PMID:24561310 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL5 protein] |
CTD |
PMID:24561310 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CCNB1 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression |
EXP ISO |
Niclosamide inhibits the reaction [Epinephrine results in increased expression of CCND1 mRNA]; Niclosamide inhibits the reaction [GCG protein results in increased expression of CCND1 mRNA]; Niclosamide inhibits the reaction [GCG protein results in increased expression of CCND1 protein]; Niclosamide inhibits the reaction [Thioacetamide results in increased expression of CCND1 mRNA]; Niclosamide inhibits the reaction [Thioacetamide results in increased expression of CCND1 protein]; Poloxamer promotes the reaction [Niclosamide inhibits the reaction [Thioacetamide results in increased expression of CCND1 mRNA]]; Poloxamer promotes the reaction [Niclosamide inhibits the reaction [Thioacetamide results in increased expression of CCND1 protein]] Niclosamide results in decreased expression of CCND1 mRNA Niclosamide analog results in decreased expression of CCND1 protein; Niclosamide results in decreased expression of CCND1 mRNA; Niclosamide results in decreased expression of CCND1 protein Niclosamide inhibits the reaction [IL6 protein results in increased expression of CCND1 mRNA]; Niclosamide inhibits the reaction [TNF protein results in increased expression of CCND1 mRNA]; Niclosamide promotes the reaction [bicalutamide results in decreased expression of CCND1 protein] |
CTD |
PMID:19160421 PMID:20215516 PMID:24552774 PMID:24736023 PMID:26297436 PMID:26964897 PMID:27338550 PMID:28284560 PMID:28500234 PMID:30143678 PMID:32961231 More...
|
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression increases expression |
ISO |
Niclosamide results in decreased expression of CCND2 mRNA Niclosamide results in increased expression of CCND2 mRNA |
CTD |
PMID:22576131 PMID:27226553 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CCND3 mRNA |
CTD |
PMID:22576131 PMID:27226553 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccne2 |
cyclin E2 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [PIK3CA protein modified form results in increased expression of CCNE2 mRNA] |
CTD |
PMID:27542212 |
|
NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632
|
|
G |
Ccng2 |
cyclin G2 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [PIK3CA protein modified form results in decreased expression of CCNG2 mRNA] |
CTD |
PMID:27542212 |
|
NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
|
|
G |
Cd40 |
CD40 molecule |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [Lipopolysaccharides affects the expression of CD40 protein] |
CTD |
PMID:24561310 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd80 |
Cd80 molecule |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [Lipopolysaccharides affects the expression of CD80 protein] |
CTD |
PMID:24561310 |
|
NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030
|
|
G |
Cd86 |
CD86 molecule |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [Lipopolysaccharides affects the expression of CD86 protein] |
CTD |
PMID:24561310 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdc37 |
cell division cycle 37, HSP90 cochaperone |
multiple interactions |
ISO |
CDC37 protein binds to and results in increased susceptibility to Niclosamide analog |
CTD |
PMID:28284560 |
|
NCBI chr 8:19,677,400...19,690,761
Ensembl chr 8:19,671,938...19,690,809
|
|
G |
Cdc42 |
cell division cycle 42 |
decreases expression decreases phosphorylation |
ISO |
Niclosamide results in decreased expression of CDC42 mRNA Niclosamide results in decreased phosphorylation of CDC42 protein |
CTD |
PMID:29251334 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdc6 |
cell division cycle 6 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CDC6 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011
|
|
G |
Cdca2 |
cell division cycle associated 2 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CDCA2 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr15:41,895,946...41,942,226
Ensembl chr15:41,895,901...41,941,611
|
|
G |
Cdca5 |
cell division cycle associated 5 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CDCA5 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 1:203,378,550...203,392,027
Ensembl chr 1:203,378,577...203,392,023
|
|
G |
Cdca8 |
cell division cycle associated 8 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CDCA8 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 5:137,176,414...137,198,686
Ensembl chr 5:137,176,417...137,198,629
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions increases expression |
ISO |
Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in decreased expression of CDH1 protein]; WNT7A protein affects the reaction [Niclosamide results in increased expression of CDH1 protein] Niclosamide results in increased expression of CDH1 mRNA; Niclosamide results in increased expression of CDH1 protein |
CTD |
PMID:25174399 PMID:26643609 PMID:30143678 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of CDH2 protein] |
CTD |
PMID:26643609 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CDK2 protein |
CTD |
PMID:29031202 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CDK4 protein |
CTD |
PMID:29031202 |
|
NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
TP53 gene mutant form inhibits the reaction [Niclosamide results in increased expression of CDKN1A mRNA]; TP53 protein mutant form inhibits the reaction [Niclosamide results in increased expression of CDKN1A mRNA] |
CTD |
PMID:30258081 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CDKN3 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
|
|
G |
Celsr3 |
cadherin, EGF LAG seven-pass G-type receptor 3 |
increases expression |
ISO |
Niclosamide results in increased expression of CELSR3 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 8:109,530,597...109,558,360
Ensembl chr 8:109,530,641...109,558,354
|
|
G |
Cenpa |
centromere protein A |
decreases expression |
ISO |
Niclosamide results in decreased expression of CENPA mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 6:25,700,142...25,711,767
Ensembl chr 6:25,700,142...25,711,675
|
|
G |
Cfp |
complement factor properdin |
increases expression |
ISO |
Niclosamide results in increased expression of CFP mRNA |
CTD |
PMID:28284560 |
|
NCBI chr X:1,162,014...1,167,576
Ensembl chr X:1,161,979...1,167,573
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
Niclosamide results in decreased phosphorylation of and affects the localization of CHUK protein |
CTD |
PMID:26116531 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression |
ISO |
Niclosamide results in decreased expression of COL1A1 mRNA |
CTD |
PMID:28824321 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Colec10 |
collectin subfamily member 10 |
increases expression |
ISO |
Niclosamide results in increased expression of COLEC10 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 7:85,744,895...85,806,368
Ensembl chr 7:85,744,895...85,805,675
|
|
G |
Crebbp |
CREB binding protein |
increases expression |
ISO |
Niclosamide results in increased expression of CREBBP mRNA |
CTD |
PMID:22576131 |
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of ACP5 mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of and affects the localization of NFATC1 protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 protein modified form]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of FOS mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of ITGB3 mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of MMP9 mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of NFATC1 mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of OCSTAMP mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of OSCAR mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of TRAF6 protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK1 protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK3 protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK8 protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK9 protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of NFKBIA protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of RELA protein] |
CTD |
PMID:28824321 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csgalnact1 |
chondroitin sulfate N-acetylgalactosaminyltransferase 1 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [PIK3CA protein modified form results in decreased expression of CSGALNACT1 mRNA] |
CTD |
PMID:27542212 |
|
NCBI chr16:20,995,210...21,330,586
Ensembl chr16:21,235,784...21,330,319
|
|
G |
Csnk1e |
casein kinase 1, epsilon |
increases expression |
ISO |
Niclosamide results in increased expression of CSNK1E mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 7:110,983,322...111,006,926
Ensembl chr 7:110,983,318...111,006,794
|
|
G |
Csrnp1 |
cysteine and serine rich nuclear protein 1 |
increases expression |
ISO |
Niclosamide results in increased expression of CSRNP1 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 8:119,704,712...119,717,767
Ensembl chr 8:119,704,713...119,718,183
|
|
G |
Ctbp1 |
C-terminal binding protein 1 |
increases expression |
ISO |
Niclosamide results in increased expression of CTBP1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr14:77,455,580...77,482,821
Ensembl chr14:77,455,696...77,482,821
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases expression decreases expression increases ubiquitination decreases activity multiple interactions |
ISO EXP |
Niclosamide results in increased expression of CTNNB1 mRNA Niclosamide results in decreased expression of CTNNB1 mRNA Niclosamide results in increased ubiquitination of CTNNB1 protein Niclosamide results in decreased activity of CTNNB1 protein Niclosamide inhibits the reaction [Epinephrine results in increased phosphorylation of CTNNB1 protein]; Niclosamide inhibits the reaction [GCG protein results in increased phosphorylation of CTNNB1 protein]; Niclosamide inhibits the reaction [Thioacetamide results in increased expression of CTNNB1 protein]; Poloxamer promotes the reaction [Niclosamide inhibits the reaction [Thioacetamide results in increased expression of CTNNB1 protein]] Niclosamide analog results in decreased expression of CTNNB1 protein; Niclosamide results in decreased expression of CTNNB1 protein Imatinib Mesylate promotes the reaction [Niclosamide results in decreased expression of CTNNB1 protein]; Niclosamide inhibits the reaction [CTNNB1 protein binds to CTNNBIP1 protein]; Niclosamide inhibits the reaction [Lithium Chloride affects the localization of CTNNB1 protein]; Niclosamide inhibits the reaction [TNF protein affects the localization of CTNNB1 protein]; Niclosamide inhibits the reaction [WNT3A protein affects the localization of CTNNB1 protein]; Niclosamide inhibits the reaction [WNT3A protein results in increased stability of CTNNB1 protein]; Niclosamide promotes the reaction [Imatinib Mesylate results in decreased expression of CTNNB1 protein] |
CTD |
PMID:19772353 PMID:21531761 PMID:22576131 PMID:24534281 PMID:24552774 PMID:24736023 PMID:25174399 PMID:26964897 PMID:27226553 PMID:27492973 PMID:28284560 PMID:30143678 PMID:32961231 More...
|
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctnnbip1 |
catenin, beta-interacting protein 1 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [CTNNB1 protein binds to CTNNBIP1 protein] |
CTD |
PMID:24534281 |
|
NCBI chr 5:159,961,961...160,010,942
Ensembl chr 5:159,961,928...160,010,939
|
|
G |
Ctsc |
cathepsin C |
decreases expression |
ISO |
Niclosamide results in decreased expression of CTSC protein |
CTD |
PMID:29480568 |
|
NCBI chr 1:142,028,386...142,059,841
Ensembl chr 1:142,028,392...142,060,387
|
|
G |
Ctsd |
cathepsin D |
decreases expression |
ISO |
Niclosamide results in decreased expression of CTSD protein |
CTD |
PMID:29480568 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsk |
cathepsin K |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA] |
CTD |
PMID:26792726 |
|
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Cxcr5 |
C-X-C motif chemokine receptor 5 |
multiple interactions |
ISO |
Niclosamide affects the reaction [FAS protein mutant form affects the expression of CXCR5 mRNA] |
CTD |
PMID:33632240 |
|
NCBI chr 8:44,842,098...44,858,425
Ensembl chr 8:44,843,413...44,857,893
|
|
G |
Cycs |
cytochrome c, somatic |
increases expression |
ISO |
Niclosamide results in increased expression of CYCS protein |
CTD |
PMID:26703449 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases activity |
ISO |
Niclosamide results in increased activity of CYP1A1 protein |
CTD |
PMID:12451431 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity increases expression |
ISO |
Niclosamide results in decreased activity of CYP1A2 protein Niclosamide results in increased expression of CYP1A2 mRNA |
CTD |
PMID:11124226 PMID:28284560 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases activity |
ISO |
Niclosamide results in decreased activity of CYP2D6 protein |
CTD |
PMID:11124226 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp39a1 |
cytochrome P450, family 39, subfamily a, polypeptide 1 |
increases expression |
ISO |
Niclosamide results in increased expression of CYP39A1 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 9:17,230,455...17,306,775
Ensembl chr 9:17,230,455...17,306,775
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity |
ISO |
Niclosamide results in decreased activity of CYP3A4 protein |
CTD |
PMID:11124226 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
Niclosamide results in increased expression of DDIT3 mRNA; Niclosamide results in increased expression of DDIT3 protein ATF3 protein affects the reaction [Niclosamide results in increased expression of DDIT3 mRNA] |
CTD |
PMID:26917416 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Decr1 |
2,4-dienoyl-CoA reductase 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of DECR1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 5:29,411,172...29,439,054
Ensembl chr 5:29,411,172...29,439,018
|
|
G |
Dmac2l |
distal membrane arm assembly component 2 like |
decreases expression |
ISO |
Niclosamide results in decreased expression of DMAC2L mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 6:88,205,580...88,223,934
Ensembl chr 6:88,205,700...88,223,933
|
|
G |
Dscc1 |
DNA replication and sister chromatid cohesion 1 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [PIK3CA protein modified form results in increased expression of DSCC1 mRNA] |
CTD |
PMID:27542212 |
|
NCBI chr 7:86,482,588...86,498,212
Ensembl chr 7:86,482,588...86,498,212
|
|
G |
Dvl1 |
dishevelled segment polarity protein 1 |
increases expression |
ISO |
Niclosamide results in increased expression of DVL1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 5:166,456,989...166,468,733
Ensembl chr 5:166,456,686...166,468,664
|
|
G |
Dvl2 |
dishevelled segment polarity protein 2 |
decreases expression multiple interactions |
ISO EXP |
Niclosamide results in decreased expression of DVL2 protein Niclosamide inhibits the reaction [Thioacetamide results in increased expression of DVL2 mRNA]; Poloxamer promotes the reaction [Niclosamide inhibits the reaction [Thioacetamide results in increased expression of DVL2 mRNA]] |
CTD |
PMID:19772353 PMID:21531761 PMID:30143678 PMID:32961231 |
|
NCBI chr10:54,723,356...54,732,823
Ensembl chr10:54,723,411...54,732,820
|
|
G |
Dvl3 |
dishevelled segment polarity protein 3 |
increases expression |
ISO |
Niclosamide results in increased expression of DVL3 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr11:80,365,446...80,382,641
Ensembl chr11:80,366,117...80,382,462
|
|
G |
E2f1 |
E2F transcription factor 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of E2F1 mRNA |
CTD |
PMID:29843133 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
E2f8 |
E2F transcription factor 8 |
decreases expression |
ISO |
Niclosamide results in decreased expression of E2F8 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098
|
|
G |
Ebf1 |
EBF transcription factor 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of EBF1 mRNA |
CTD |
PMID:27226553 |
|
NCBI chr10:29,095,858...29,489,142
Ensembl chr10:29,099,933...29,487,665
|
|
G |
Echdc1 |
ethylmalonyl-CoA decarboxylase 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ECHDC1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 1:28,476,354...28,507,173
Ensembl chr 1:28,476,200...28,507,319
|
|
G |
Echs1 |
enoyl-CoA hydratase, short chain 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ECHS1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 1:194,895,036...194,903,863
Ensembl chr 1:194,895,036...194,903,884
|
|
G |
Egf |
epidermal growth factor |
decreases expression multiple interactions |
ISO |
Niclosamide results in decreased expression of EGF mRNA; Niclosamide results in decreased expression of EGF protein Niclosamide inhibits the reaction [EGF protein results in increased expression of HIF1A mRNA]; Niclosamide inhibits the reaction [EGF protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:30779072 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression decreases phosphorylation |
ISO |
Niclosamide analog results in decreased expression of EGFR protein; Niclosamide results in decreased expression of EGFR mRNA; Niclosamide results in decreased expression of EGFR protein Niclosamide results in decreased phosphorylation of EGFR protein |
CTD |
PMID:28284560 PMID:28426875 PMID:30779072 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
Niclosamide results in increased expression of EGR1 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases expression multiple interactions |
ISO |
Niclosamide results in increased expression of EIF2AK3 mRNA ATF3 protein affects the reaction [Niclosamide results in increased expression of EIF2AK3 mRNA]; Niclosamide results in increased expression of and results in increased phosphorylation of EIF2AK3 protein |
CTD |
PMID:26917416 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation |
ISO |
Niclosamide results in increased phosphorylation of EIF2S1 protein |
CTD |
PMID:26917416 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
multiple interactions |
ISO |
Niclosamide promotes the reaction [EIF4E protein binds to EIF4EBP1 protein] |
CTD |
PMID:19771169 |
|
NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
decreases expression multiple interactions decreases phosphorylation |
ISO |
Niclosamide analog results in decreased expression of EIF4EBP1 protein modified form; Niclosamide results in decreased expression of EIF4EBP1 protein modified form Niclosamide inhibits the reaction [MTOR protein results in increased phosphorylation of EIF4EBP1 protein]; Niclosamide promotes the reaction [EIF4E protein binds to EIF4EBP1 protein] Niclosamide results in decreased phosphorylation of EIF4EBP1 protein |
CTD |
PMID:19771169 PMID:28284560 PMID:30258081 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Endod1 |
endonuclease domain containing 1 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [PIK3CA protein modified form results in increased expression of ENDOD1 mRNA] |
CTD |
PMID:27542212 |
|
NCBI chr 8:11,209,123...11,238,680
Ensembl chr 8:11,211,110...11,238,892
|
|
G |
Eno2 |
enolase 2 |
increases expression |
ISO |
Niclosamide results in increased expression of ENO2 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Eno3 |
enolase 3 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ENO3 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr10:55,370,531...55,375,921
Ensembl chr10:55,366,975...55,375,921
|
|
G |
Ep300 |
E1A binding protein p300 |
increases expression |
ISO |
Niclosamide results in increased expression of EP300 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Eps8l3 |
EPS8 like 3 |
increases expression |
ISO |
Niclosamide results in increased expression of EPS8L3 mRNA |
CTD |
PMID:28284560 |
|
Ensembl chr 2:195,514,692...195,528,085
|
|
G |
Fam83d |
family with sequence similarity 83, member D |
decreases expression |
ISO |
Niclosamide results in decreased expression of FAM83D mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 3:147,421,941...147,441,211
Ensembl chr 3:147,421,908...147,441,192
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO EXP |
Niclosamide affects the reaction [FAS protein mutant form affects the expression of BCL6 mRNA]; Niclosamide affects the reaction [FAS protein mutant form affects the expression of BCL6 protein]; Niclosamide affects the reaction [FAS protein mutant form affects the expression of CXCR5 mRNA]; Niclosamide affects the reaction [FAS protein mutant form affects the expression of IL21 protein]; Niclosamide affects the reaction [FAS protein mutant form affects the expression of IL6 protein]; Niclosamide affects the reaction [FAS protein mutant form affects the expression of PRDM1 mRNA]; Niclosamide affects the reaction [FAS protein mutant form affects the expression of TCF7 protein]; Niclosamide affects the reaction [FAS protein mutant form affects the phosphorylation of STAT3 protein]; Niclosamide inhibits the reaction [Doxorubicin results in increased expression of FAS mRNA] Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of FAS mRNA] |
CTD |
PMID:28318631 PMID:33632240 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of FGF1 mRNA; Niclosamide results in decreased expression of FGF1 protein |
CTD |
PMID:25174399 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
multiple interactions decreases expression |
ISO |
[Niclosamide co-treated with bicalutamide] results in decreased expression of FKBP5 mRNA Niclosamide results in decreased expression of FKBP5 mRNA |
CTD |
PMID:28500234 |
|
NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [Doxorubicin results in increased expression of FN1 protein] HIPK2 protein inhibits the reaction [Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA]]; Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA] |
CTD |
PMID:28318631 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of FOS mRNA] Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of FOS protein] |
CTD |
PMID:26792726 PMID:28824321 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Niclosamide results in increased expression of FOSB mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression |
ISO |
Niclosamide results in increased expression of FOSL1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Foxm1 |
forkhead box M1 |
multiple interactions decreases expression |
ISO |
Imatinib Mesylate promotes the reaction [Niclosamide results in decreased expression of FOXM1 protein]; Niclosamide inhibits the reaction [TNF protein affects the localization of FOXM1 protein]; Niclosamide promotes the reaction [Imatinib Mesylate results in decreased expression of FOXM1 protein] |
CTD |
PMID:27492973 |
|
NCBI chr 4:161,639,561...161,652,012
Ensembl chr 4:161,638,816...161,650,684
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [Adenosine Triphosphate results in increased expression of FSCN1 mRNA] |
CTD |
PMID:29733962 |
|
NCBI chr12:11,597,042...11,610,183
Ensembl chr12:11,597,048...11,610,211
|
|
G |
Fzd1 |
frizzled class receptor 1 |
affects localization |
ISO |
Niclosamide affects the localization of FZD1 protein |
CTD |
PMID:19772353 |
|
NCBI chr 4:29,310,303...29,314,701
|
|
G |
Fzd2 |
frizzled class receptor 2 |
decreases expression |
ISO |
Niclosamide results in decreased expression of FZD2 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr10:87,561,866...87,563,776
Ensembl chr10:87,561,326...87,565,334
|
|
G |
Fzd5 |
frizzled class receptor 5 |
increases expression |
ISO |
Niclosamide results in increased expression of FZD5 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 9:66,117,370...66,119,127
Ensembl chr 9:66,113,112...66,121,457
|
|
G |
Fzd9 |
frizzled class receptor 9 |
decreases expression |
ISO |
Niclosamide results in decreased expression of FZD9 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr12:21,427,084...21,429,398
Ensembl chr12:21,427,084...21,429,398
|
|
G |
Gcg |
glucagon |
multiple interactions |
EXP |
Niclosamide inhibits the reaction [GCG protein results in increased abundance of Cyclic AMP]; Niclosamide inhibits the reaction [GCG protein results in increased expression of CCND1 mRNA]; Niclosamide inhibits the reaction [GCG protein results in increased expression of CCND1 protein]; Niclosamide inhibits the reaction [GCG protein results in increased expression of MYC mRNA]; Niclosamide inhibits the reaction [GCG protein results in increased phosphorylation of CTNNB1 protein] |
CTD |
PMID:26964897 |
|
NCBI chr 3:47,113,914...47,122,929
Ensembl chr 3:47,113,914...47,122,929
|
|
G |
Got2 |
glutamic-oxaloacetic transaminase 2 |
increases expression |
ISO |
Niclosamide results in increased expression of GOT2 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr19:9,174,304...9,199,995
Ensembl chr19:9,174,311...9,199,994
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases expression decreases phosphorylation |
ISO |
Niclosamide results in decreased expression of GSK3B mRNA Niclosamide results in decreased phosphorylation of GSK3B protein |
CTD |
PMID:22576131 PMID:30143678 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gtse1 |
G-2 and S-phase expressed 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of GTSE1 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 7:116,949,997...116,966,826
Ensembl chr 7:116,950,053...116,966,806
|
|
G |
Hadh |
hydroxyacyl-CoA dehydrogenase |
decreases expression |
ISO |
Niclosamide results in decreased expression of HADH mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
decreases expression increases expression |
ISO |
Niclosamide results in decreased expression of HAMP mRNA Niclosamide results in increased expression of HAMP mRNA |
CTD |
PMID:25633564 PMID:28284560 |
|
NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891
|
|
G |
Hbp1 |
HMG-box transcription factor 1 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [PIK3CA protein modified form results in decreased expression of HBP1 mRNA] |
CTD |
PMID:27542212 |
|
NCBI chr 6:48,529,633...48,555,775
Ensembl chr 6:48,529,372...48,555,787
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
decreases expression multiple interactions |
ISO EXP |
Niclosamide results in decreased expression of HES1 protein Niclosamide inhibits the reaction [Doxorubicin results in increased expression of HES1 mRNA] Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of HES1 mRNA]; Niclosamide inhibits the reaction [Thioacetamide results in increased expression of HES1 mRNA]; Poloxamer promotes the reaction [Niclosamide inhibits the reaction [Thioacetamide results in increased expression of HES1 mRNA]] |
CTD |
PMID:19160421 PMID:28318631 PMID:32961231 |
|
NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192
|
|
G |
Hey1 |
hes-related family bHLH transcription factor with YRPW motif 1 |
multiple interactions |
ISO EXP |
Niclosamide inhibits the reaction [Doxorubicin results in increased expression of HEY1 mRNA] Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of HEY1 mRNA] Niclosamide inhibits the reaction [PIK3CA protein modified form results in decreased expression of HEY1 mRNA] |
CTD |
PMID:27542212 PMID:28318631 |
|
NCBI chr 2:93,096,706...93,100,316
Ensembl chr 2:93,095,498...93,100,312
|
|
G |
Hey2 |
hes-related family bHLH transcription factor with YRPW motif 2 |
multiple interactions increases expression |
EXP ISO |
Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of HEY2 mRNA] Niclosamide inhibits the reaction [Doxorubicin results in increased expression of HEY2 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Niclosamide results in increased expression of HEY2 mRNA] |
CTD |
PMID:19160421 PMID:28318631 |
|
NCBI chr 1:26,822,131...26,832,218
Ensembl chr 1:26,822,131...26,832,218
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
decreases expression multiple interactions |
ISO |
Niclosamide results in decreased expression of HIF1A mRNA; Niclosamide results in decreased expression of HIF1A protein Niclosamide inhibits the reaction [EGF protein results in increased expression of HIF1A mRNA] |
CTD |
PMID:30779072 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hipk2 |
homeodomain interacting protein kinase 2 |
multiple interactions |
ISO EXP |
Niclosamide inhibits the reaction [Doxorubicin results in increased expression of HIPK2 mRNA]; Niclosamide inhibits the reaction [Doxorubicin results in increased expression of HIPK2 protein] HIPK2 protein inhibits the reaction [Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA]]; HIPK2 protein inhibits the reaction [Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]]; HIPK2 protein inhibits the reaction [Niclosamide inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]]; Niclosamide inhibits the reaction [TGFB1 protein promotes the reaction [SMAD3 protein binds to HIPK2 promoter]]; Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of HIPK2 protein] Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of HIPK2 mRNA]; Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of HIPK2 protein] |
CTD |
PMID:28318631 |
|
NCBI chr 4:67,439,327...67,619,223
Ensembl chr 4:67,440,501...67,619,223
|
|
G |
Hmmr |
hyaluronan-mediated motility receptor |
decreases expression |
ISO |
Niclosamide results in decreased expression of HMMR mRNA |
CTD |
PMID:28284560 |
|
NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060
|
|
G |
Hoxa1 |
homeobox A1 |
increases expression |
ISO |
Niclosamide results in increased expression of HOXA1 |
CTD |
PMID:26820057 |
|
NCBI chr 4:81,255,814...81,258,504
Ensembl chr 4:81,255,883...81,258,504
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO EXP |
Niclosamide inhibits the reaction [Doxorubicin results in increased expression of ICAM1 mRNA] Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of ICAM1 mRNA] |
CTD |
PMID:28318631 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
affects response to substance |
ISO |
IGF1R protein affects the susceptibility to Niclosamide |
CTD |
PMID:27497986 |
|
NCBI chr 1:121,549,839...121,838,545
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Igll1 |
immunoglobulin lambda-like polypeptide 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of IGLL1 mRNA |
CTD |
PMID:27226553 |
|
NCBI chr11:84,138,847...84,142,238
Ensembl chr11:84,138,910...84,142,216
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
affects localization |
ISO |
Niclosamide affects the localization of IKBKB protein |
CTD |
PMID:26116531 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Ikbkg |
inhibitor of nuclear factor |